2012N139436 _03 CONFIDENTIA L
The GlaxoSmithKline group of companies MEA115666
1TITLE PA GE
Division: World wide Development
Information Type: Protocol Amendment
Title: MEA115666: A multi -centre, open- label, long term safet y study
of mepolizumab in asthmatic subjects who participated in the
MEA112997 trial.
Compound Number: SB-240563
Development Phase: IIIa
Effective Date: 19-JUN-2015
Protocol Amendment Number:  03
Author (s):
Copy right 2015 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised cop ying or use of this information is prohibited. 2017N325880_00
[COMPANY_003]
2012N139436 _03 CONFIDENTIA L
The GlaxoSmithKline group of companies MEA115666
2Revision Chronology
GlaxoSmith Kline
Document NumberDate Version
2012N139436_00 2012- MAY -31 Original
2012N139436_01 2012- AUG-21 Amendment No.: 1
To clarify  that the rationale and objective of the study  includes long -term provision 
of mepoliz umab therap y to subjects who have severe asthma and participated in 
MEA112997
To clarify  that onl y monoclonal antibodies are excluded, rather than all biologics
To clarify  reason for more frequent safety  monitoring at the start of the study  
To correct Inc lusion criterion 5 from Randomisation Visit to Visit 2
To add exclusion criterion for significant cardiovascular disease
To correct inconsistencies between protocol text and the Time and Events Table
To correct bilirubin exclusion criterion at visit 2
To expand on requirements for designating a subject as lost to follow -up
To add visit window for the follow -up visit
To move baseline spi[INVESTIGATOR_725474]
To clarify  that all subjects will have an immunogenicity  test [ADDRESS_990256] dose
To correct Section [IP_ADDRESS] wording “Efficacy ” to “Safet y”
To add reference to support Appendix 6 and remove 3 references which are not cited 
in the protocol.
To add Appendix 5 and Appendix 6 and amended Section 6.1 and Section 6.3.9. to 
support the determination of exclusion criteria 4
2012N139436_02 2013- MAR -06 Amendment No.02
To add two additional immunogenicit y sample assessment time points when the 
100mg vial is introduced. 
To allow other s yringe sizes for study drug administration
Toallow for stud y drug administration in the upper thigh or the arm
To add the prohibited non-drug therapi[INVESTIGATOR_725475] 5.7.2
To list Adverse Events and Serious Adverse Events on the same line in Table 3
To correct a formatting error for S ection 4.6 2017N325880_00
2012N139436 _03 CONFIDENTIA L
The GlaxoSmithKline group of companies MEA115666
3To remove specific test name [CONTACT_725495] C positive sample
To delete redundant text in Section [IP_ADDRESS]
To remove from Section 6.3.7 the requirement to report outcome of pregnancy  in 
female partners of male subjects
To include anal yses of immunogenici ty data in S ection 8.3 and to clarify  when 
interim analy ses will be performed
2012N139436_03 2015- JUN-19 Amendment No. 3
To reduce the Follow -up visit period from [ADDRESS_990257] dose of IP 
To update the time limit from reconstitution to a dministration of I P 2017N325880_00
 
P P D 2 0 1 7 N 3 2 5 8 8 0 _ 0 0 
2012N139436_0 3 CONFIDENTIA L
MEA115666
5SPONSOR INFORMA TION PAGE
Clinical Study  Identifier: MEA115666
Sponsor Legal Registered Address
GlaxoSmithKl ine Research & Development Limited
Iron Bridge Road
Stockley  Park West , Uxbridge ,Middlesex ,UB11 1BU ,[LOCATION_006]
Telephone:  
GlaxoSmithKline Research & Development Limited
Five Moore Drive
P.O. [ZIP_CODE]
Research Triangle Park ,NC [ZIP_CODE] , [LOCATION_003]
Telephone: 
Sponsor Global Medical Monitor Contact [CONTACT_7171]:  
 MD (Director, Respi[INVESTIGATOR_696]  & Immuno -Inflammation Medicine 
Development Centre)
Tel: 
Mobile: 
Sponso r Global Back -up Medical Monitor Contact [CONTACT_7171]:  
 MD (Director, Respi[INVESTIGATOR_696]  & Immuno -Inflammation Medicine 
Development Centre)
Tel:
Mobile: 
Sponsor Serious Adverse Events (SAE) Contact [CONTACT_7171]: 
Case Management Group, Global Clinical Safety  and Pharmacovigilance (GCSP)
Email: 
Fax: 
Regulatory  Agency  Identify ing Number(s): IND No. 006971, 
EudraCT No. 2012- [ADDRESS_990258] to ensure that site 
staff receives the appropriate information throughout the study . 
Investigator Name:
[CONTACT_132026]:
Investigator Phone Number:
Investigator Signature [CONTACT_1782] 2017N325880_00
2012N139436_0 [ADDRESS_990259] OF ABBREVIATION S........................................................................................... 10
PROTOCOL SUMMARY ............................................................................................... 12
1.INTRODUCTION ................................
.................................................................... 15
1.1. Background ................................................................................................ 15
1.2. Rationale .................................................................................................... 15
2.OBJECTIVE(S) ...................................................................................................... [ADDRESS_990260] SELECTION AND W ITHDRAW AL CRITERIA ....................................... 18
4.1. Number of Subjects .................................................................................... 18
4.2. Inclusion Criteria ......................................................................................... 18
4.3. Exclusion Criteria ........................................................................................ 19
4.4. Visit 2 Criteria ............................................................................................. 20
4.5. Withdrawal Criteria ..................................................................................... 21
4.6. Screening/Run- in Failures .......................................................................... [ADDRESS_990261] Accountability ................................................................................ 23
5.6. Treatment Compliance................................................................................ 23
5.7. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014] .................................... 23
5.7.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .......................... 23
5.7.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] ......................... 23
5.8. Treatment after the E nd of the Study .......................................................... 24
5.9. Treatment of Study Treatment Overdose .................................................... 24
6.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 25
6.1. Critical Baseline Assessments .................................................................... 28
6.2. Efficacy ....................................................................................................... 29
6.2.1. Efficacy Endpoints ....................................................................... 29
[IP_ADDRESS]. Exacerbations ............................................................. 29
[IP_ADDRESS]. Pulmonary Function Testing ....................................... 29
[IP_ADDRESS]. Asthma Control Questionnaire -5 (ACQ) ...................... 29
6.3. Safety ......................................................................................................... 30
6.3.1. Safety Endpoints .......................................................................... 30
6.3.2. Liver chemistry stoppi[INVESTIGATOR_23879] ............................. 30
6.3.3. Adverse Events ............................................................................ 33
[IP_ADDRESS]. Definition of an AE ...................................................... 33
[IP_ADDRESS]. Definition of a SAE ..................................................... 34 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
86.3.4. Laboratory and Other Safety Assessment Abnormalities 
Reported as AEs and SAE s......................................................... 35
6.3.5. Cardiovascular Events ................................................................ .36
6.3.6. Death Events ............................................................................... 36
6.3.7. Pregnancy ................................................................................... 36
6.3.8. Time Period and Frequency of Detecting AEs and SA Es............. 37
6.3.9. Prompt Reporting of Serious Adverse Events and Other 
Events to [COMPANY_004] ............................................................................. 37
[IP_ADDRESS]. Regulatory reporting requirements for SAEs .............. 39
6.3.10. Other Safety Outcome s............................................................... 39
[IP_ADDRESS]. Vital Signs .................................................................. 39
[IP_ADDRESS]. Twelve-lead electrocardiogram ................................... 39
[IP_ADDRESS]. Clinical Laboratory Parameters ................................... 40
6.4. Immunogenicity ........................................................................................... 40
7.DATA MANAGEMENT ........................................................................................... 40
8. DATA ANALYSIS AND STATISTICAL CONSIDERATIONS ................................... 41
8.1. Hypotheses ................................................................................................ .41
8.2. Study Design Considerations ...................................................................... 41
8.2.1. Sample Size Assumptions ........................................................... 41
8.2.2. Sample Size Sensitivity ................................................................ 41
8.2.3. Sample Size Re- estimation .......................................................... 41
8.3. Data Analysis Considerations ..................................................................... 41
8.3.1. Analysis Populations .................................................................... 41
8.3.2. Analysis Data Sets ....................................................................... 41
8.3.3. Treatment Comparisons .............................................................. 41
[IP_ADDRESS]. Primary Comparisons of Interest ................................ 41
[IP_ADDRESS]. Other Comparisons of Interest .................................... 42
8.3.4. Interim Analysis ........................................................................... 42
8.3.5. Key Elements of Analysis Plan .................................................... 42
[IP_ADDRESS]. Efficacy Analyses ....................................................... 42
[IP_ADDRESS]. Safety Analyses .......................................................... 42
[IP_ADDRESS]. Immunogenicity Analyses ........................................... [ADDRESS_990262] CONSIDERATIONS ............................................................... 42
9.1. Posting of Information on Pu blicly Available Clinical Trial Registers ............ 42
9.2. Regulatory and Ethical Considerations, Including the Informed 
Consent Process ........................................................................................ 42
9.3. Quality Control (Study Monitoring) .............................................................. 43
9.4. Quality Assurance ....................................................................................... 44
9.5. Study and Site Closure ............................................................................... 44
9.6. Records Retention ...................................................................................... 44
9.7. Provision of Study Results to Investigators, Posting of Information 
onPublicly Available Clinical Trials Registers and Publication .................... 45
9.8. Independent Data Monitoring Committee (IDMC) ....................................... 45
10.REFERENCES ....................................................................................................... 46
11.APPENDICES ........................................................................................................ 48
11.1. Appendix 1: Country Specific Requirements ............................................... 48
11.2. Appendix 2: Acceptable Birth Control .......................................................... 49 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
911.3. Appendix 3: Liver Chemistry Stoppi[INVESTIGATOR_23881] ...................... 51
11.4. Appendix 4: Anaphylaxis Criteria ................................................................ 52
11.5. Appendix 5: Cardiovascular Screening Questions ...................................... 53
11.6. Appendix 6: [LOCATION_001] Heart Association Functional Classification 
of Congest ive Heart Failure ........................................................................ 54
11.7. Appendix 7: Protocol Changes .................................................................... [ADDRESS_990263]  Pressure
CS Corticosteroid
DNA Deox yribonucleic acid
ECG Electrocardiogram
eCRF Electronic Case report form
ED Emergency  Department
ERS European Respi[INVESTIGATOR_645955]1 Forced expi[INVESTIGATOR_4034] 1 second
FVC Forced vital capacit y
GCP Good clinical practice
GCSP Global Clinical Safety  and Pharmacovigilance
GINA Global I nitiative for Asthma
[COMPANY_004] GlaxoSmithKline
HBsAg Hepatitis B Surface Antigen
HIV Hum an Immunodeficiency  Virus
IDMC Independent Data Monitoring Committee
IC50 Inhibitory  Concentration 50%
ICS Inhaled corticosteroids
ICU Intensive Care Unit
IEC Independent ethics committee
Ig Immunoglobulin
IL Interleukin
IM Intramuscular
IP Invest igational Product
IRB Institutional review board
ITT Intent to Treat
IUD Intrauterine Device
IV Intravenous
IVRS Interactive voice response sy stem
LABA Long -acting beta -2-agonists
LTRA Leukotriene receptor antagonist
MedDRA Medicinal dictionary  forregulatory  activities
mcg Micrograms
MDI Metered Dose Inhaler
mg Milligram
N/A Not applicable
NHANES National Health and Nutrition Examination Survey
NHLBI National Heart Lung and Blood Institute
OCS Oral corticosteroids
OLE Open Label Extension S tudy 2017N325880_00
2012N139436_0 [ADDRESS_990264] Upper Limit of Normal
Trademark Information
Trademarks of the GlaxoSmithKline
group of companiesTrademarks not owned by [CONTACT_561937] 2017N325880_00
2012N139 436_03 CONFIDENTIA L
MEA115666
12PROTOCOL SUMMA RY
RATIONALE
This study  will provide long term safet y and immunogenicity  data when mepolizumab is 
administered subcutaneously  (SC) in subjec ts with severe, refractory  asthma and a history  
of eosinophilic inflammation.  Additionally , this study  will inform on the safety  and 
immunogenicit y profile when mepolizumab therapy is reinstituted in subjects following a 
cessation in drug therap y. 
This t rial also provides subjects who participated in the MEA112997 study, and meet the 
current trial eligibility  criteria, the option of receiving treatment with mepolizumab, as an 
add-on to their standard of care treatment for severe asthma. 
OBJECTIVE(S)
PRIMARY
The primary  objective of this study  is to describe the long -term safet y profile of 
mepolizumab. 
SECONDARY
To provide long -term treatment with mepolizumab to subjects who participated in 
MEA112997
To evaluate the effects of mepolizumab on a range of cl inical markers of asthma control 
STUDY DESIGN
This is a multi -centre, open -label, long term, safety  study  of mepolizumab100 mg 
administered SC in addition to standard of care in subjects with severe, refractory  asthma 
and a history  of eosinophilic inflamm ation.  Subjects who participated in the 
MEA112997 trial will be offered the opportunit y to consent for this study. All subjects 
will have experienced a gap of at least [ADDRESS_990265] double -blind 
study  medication in MEA112997.
At Vi sit 1, subjects will undergo an initial screening to assess their eligibility to 
participate in this study .  This screening will include: informed consent, vital signs, 
update of medical history, immunogenicit y status based on MEA112997 data, smoking 
status, prior monoclonal antibody  use, and exacerbations post completion of 
MEA112997.  Subjects meeting the Visit [ADDRESS_990266] mepolizumab dose at Visit 2.  Subjects will continue to receive 
mepolizumab SC in jections approximately  every  4 weeks until either:
The risk/benefit profile for the subject is no longer positive in the opi[INVESTIGATOR_75576]
the subject’s ph ysician withdraws the subject or 
the subject withdraws consent or
the sponsor discontinues development of mepolizumab or 
the sponsor discontinues the study in the relevant participating country or 
mepolizumab becomes commercially  available in the relevant participating 
country
Subjects will remain on standard of care asthma therap y, which may be adjusted during 
the study , at the discretion of their phy sician. The use of Xolair (omalizumab) or an y 
other monoclonal antibody  will not be permitted during the course of the study . 
Subjects will be monitored in the clinic approximately  every  4 weeks to assess adverse 
events and asthma status.  The Asthma Control Questionnaire -5 (ACQ) will be used to 
assist the investigator in assessing the subject’s asthma status along with spi[INVESTIGATOR_725476].  As some subjects may  have previously  received placebo while 
participating in the MEA112997 study  and are naive to mepolizumab, safety lab 
monitoring will be more frequent at the start of the study .  Appropriate safety  labs will be 
drawn prior to starting treatment and then at week 4, 8, 12, 24, 36 and 48.  Thereafter, 
these will be collected every  24 weeks.  Labs will also be obtained at 4 weeks after 
discontinuing mepolizumab.  Subjects discontinuing mepolizumab treatment should be 
monitored for exacerbation of their asthma.
Serum samples for a nti-mepolizumab antibody  measurements will be obtained from all 
subjects at Weeks 0, 4, 24 and 48 of the initial y ear, week 24 and 48 for every  additional 
year, as well as at the Follow -up Visit. Any  anti-mepolizumab antibody  positive sample 
will be tested for neutralization antibody .
A maximum of two additional anti- mepolizumab antibody  samples will be obtained; one 
immediately  prior to the first dose and the other prior to the second dose with the 100mg 
mepolizumab vial. I f the first or second dose coinci des with a visit where an 
immunogenicit y sample is alread y required, it is not necessary to obtain an additional 
sample.
The number of subjects participating in this trial will be no greater than the number of 
subjects randomised into MEA112997 who also r eceived 2 doses of study medication 
which is 608 subjects.
The study  closure process will begin, on a country by  [CONTACT_619291], as mepolizumab 
becomes commerciall y available for prescription.  Please see the SPM for more details. 2017N325880_00
2012N139 436_03 CONFIDENTIA L
MEA115666
14Stud y Endpoints/Assessment s
Primary Endpoint
Adverse Events
Secondary Endpoints
Frequency  of positive anti -mepolizumab binding antibodies and neutralizing 
antibodies
Annualized rate of exacerbations
Asthma Control Questionnaire score
FEV 1measured b y clinic spi[INVESTIGATOR_038]
Number of wit hdrawals due to lack of efficacy
Number of withdrawals due to adverse events
Number of hospi[INVESTIGATOR_699857]
Frequency  of both s ystemic (i.e., allergic/IgE -mediated and non-allergic)  and local 
site  reaction s
12 Lead ECG parameters
Vital signs
Clinical L aboratory  Parameters 2017N325880_00
2012N139436_0 [ADDRESS_990267]  inflammation seen in asthma and are considered a central cause in the 
pathogenesis of asthma [ Wardlaw , 2000]. The expression of interleukin (IL) -5 is elevated 
in bronchoalveolar lavage (BAL) fluid and bro nchial biopsies in patients with asthma  
[Hamid, 1991]. Moreover, the level of IL -5 in BAL fluid and the bronchial mucosa 
correlates with disease severity  [Robinson , 1992; Robinson , 1993; Humbert , 1997]. The 
cytokine IL -5 promotes eosinophil differentiation, recruitment and survival 
[Clutterbuck, 1989; Wang , 1989]. Thus a therapeutic strategy  which blocks IL -5, thereby  
[CONTACT_725490], may  have therapeutic benefit in asthma.
Currently  available therapi[INVESTIGATOR_699858] y effective at controlling asthma s ymptoms and 
airway  inflammation in the majority
 of patients [ Bateman , 2004]. Inhaled corticosteroids 
reduce airway  inflammation and sputum eosinophils in most asthmatics [ Kips , 2002].  
However, a proportion of asthma patients remain uncontrolled despi[INVESTIGATOR_725477] y including high dose inhaled corticosteroids (I CS) plus additional controller 
therap y, i.e. treatment at Step 5/6 and Step 4/5 according to the NHLBI Guidelines for the 
Diagnosis and Treatment of Asthma [ NHLBI , 2008] and the Global I nitiative for Asthma 
guidelines [ GINA, 2008], respectivel y. This severe uncontrolled, refractory population 
suffers from persistent s ymptoms and acute exacerbations of their asthma. 
Patients with severe asthma have significant morbidity  and mortality  risk; they  contribute 
disproportionately  to health care and societal costs of the disease, and costs are 
particularl y high in those with frequent exacerbations. In MEA112997 subjects had 
features of severe, refractory  asthma as described in the ATS workshop on refractory  
asthma [ ATS workshop, 2000] and additionally  demonstrated marker s of eosinophilic 
inflammation.  Together these criteria were useful to identify  a severe eosinophilic 
asthma population that continued to exacerbate despi[INVESTIGATOR_725478] y 
marketed asthma medications.  This severe, eosinophilic population is the subset of 
asthmatics most likely  to benefit from treatment with mepolizumab. Mepolizumab is a 
humanised anti -IL-5 antibody  (IgG1 kappa) currently  in clinical development. 
1.2. Rationale
This study  will provide long term safet y and immunogenicity  data when mepolizumab is 
administered subcutaneously  (SC) to subjects with severe, refractory  asthma with a 
history  of eosinophilic inflammation.  Additionally , this study  will inform on the safet y 
and immunogenicit y profile when mepolizumab therap y is reinstitut ed in subjects 
following a cessation in drug therap y.  
This trial also provides subjects who participated in the MEA112997 study, and meet the 
current trial eligibility  criteria, the option of receiving treatment with mepolizumab, as an 
add-on to their standard of care treatment for severe asthma. 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
162. OBJECTIVE(S)
Primary Objective
The primary  objective of this study  is to describe the long -term safet y profile of 
mepolizumab. 
Secondary Objectives
To provide long -term treatment with mepolizumab to subjects who participated in 
MEA112997
To evaluate the effects of mepolizumab on a range of clinical markers of asthma 
control 
3. INVESTIGA TIONAL PLA N
3.1. Stud y Design
Protocol waivers or exemptions are not allowed with the exception of immediate safety  
concerns. Therefore, adherence to the study  design requirements, including those 
specified in the Time and Events Table, are essential and required for stud y conduct. 
Supplementary  study  conduct information not mandated to be present in this protocol is 
provided in the accompany ing Study  Procedures Manual (SPM). The SPM will provide 
the site personnel with administrative and detailed technical information that does not 
impact subject safet y.
This is a multi -centre, open -label long term safet y study  of [ADDRESS_990268] double -blind study  medication in MEA112997.
At Visit 1, subjects will undergo an initial screening to assess their eligibility to 
participate in this study . This screening will include: informed consent, vital signs, 
updat e of medical history, immunogenicit y status based on MEA112997 data, smoking 
status, prior monoclonal antibody  use, and exacerbations post completion of 
MEA112997.  Subjects meeting the Visit [ADDRESS_990269] mepolizumab dose at Visit 2.  Subjects will continue to receive 
mepolizumab SC injections approximately  every  4 weeks until either:
The risk/benefit profile for the subject is no longer positive in the opi[INVESTIGATOR_75576]
the subject’s ph ysician withdraws the subject or 
the subject withdraws consent or
the sponsor discontinues development of mepolizumab or
the sponsor discontinues the study  in the relevant participating country  or
mepolizumab becomes commercially  available in the relevant parti cipating 
country
All subjects will be dosed with the 250mg vial up until such time that the 100mg vial is 
available at the site.  Once the 100mg vial is available at the site, all subjects will switch 
to dosing with the 100mg vial at the next treatment vis it and will be dosed with the100mg 
vial for the remainder of the study .
Subjects will remain on standard of care asthma therap y, which may  be adjusted during 
the study , at the discretion of their phy sician. The use of Xolair (omalizumab) or an y 
other monoc lonal antibody  will not be permitted during the course of the study .  
At each clinic visit, adverse events will be assessed, and appropriate safet y labs will be 
obtained as per the Time and Events schedule (see Table 2 and Table 3).  As some 
subjects will be naive to mepolizumab, safety  lab monitoring will be more frequent at the 
start of the study .  Exacerbations will also be reviewed at each clinic visit.
The study  closur e process will begin, on a country by  [CONTACT_619291], as mepolizumab 
becomes commerciall y available for prescription.  Please see the SPM for more details.
3.2. Discussion of Design
This study  will allow subjects that were randomised into MEA112997 study to rein stitute 
(or initiate treatment if a placebo subject) mepolizumab as adjunctive therapy . Subjects in 
MEA112997 could have received mepolizumab or placebo. Thus, the Investigator will 
need to review the randomization code to aid their assessment of whether a subject may  
receive benefit from study participation in MEA115666. For example, subjects receiving 
placebo during MEA112997 may  not have demonstrated a positive clinical response, 
nonetheless, may  be considered appropriate for the current stud y as all s ubjects will 
receive mepolizumab. Investigators should continue subjects on their baseline asthma 
therap y and adjust this therap y as needed in response to improving or worsening asthma. 
All changes in asthma therapy will be captured in the source and eCRF .
Subjects will be evaluated in the clinic approximately  every  4 weeks, to assess adverse 
events and asthma status. The Asthma Control Questionnaire (ACQ -5) will be used to 
assist the investigator in assessing the subject’s asthma status along with spi[INVESTIGATOR_105222]. 2017N325880_00
2012N139436_0 [ADDRESS_990270] a yearly assessment of risk/benefit of 
mepolizumab therapy  performed by  [CONTACT_093]. The investigator should review the 
frequency  of exacerbations, blood eosinophil suppression, and the occurrence of 
treatme nt related adverse events, and an y other relevant assessments for each subject.  
Those subjects with an unfavourable risk: benefit ratio, in the opi[INVESTIGATOR_871], 
should be withdrawn from the study .
The dose selected for the current stud y is bas ed on the results of the MEA112997 study , 
which investigated a 10 -fold dose range from 75mg to 750mg administered IV every  4 
weeks.  All 3 doses investigated (75mg, 250mg and 750mg) resulted in a clinically  
significant reduction in the frequency  of severe exacerbations when compared to placebo, 
with a reduction of 48% occurring in the 75mg treatment arm.  All 3 doses produced a 
marked and sustained suppression of blood eosinophils throughout the dose interval. The 
safet y profile was similar across all treat ment arms and was similar to placebo. Further 
details are available in the Clinical I nvestigator’s Brochure (CIB). [ GlaxoSmithKline 
Document Number CM2003/[ZIP_CODE]/07]. As the SC route is generall y preferred b y 
patients and a SC route of administration is easy  to administer and cost -effective, a SC 
route of administration has been chosen for this study .  
A PK/PD model has been developed for mepolizumab with data obtained from 5 prior 
asthma studies and 1 healthy volunteer stud y.  Two of these 5 studies, administered 
mepolizumab via the SC route.  The model well describes the relationship between 
plasma mepolizumab concentration and eosinophil counts (irrespective of the route of 
administration), with an IC 50(the conce ntration at which 50% of the maximum reduction 
of eosinophils) of 226ng/ml [ GlaxoSmithKline Document Number CM2003/[ZIP_CODE]/07].  
Based on prior PK studies, the bioavilability of mepolizumab administered SC into the 
the upper arm is approximately  75% [ GlaxoSmithKline Document Number 
CM2003/[ZIP_CODE]/07 ], and therefore a dose of 100mg SC is anticipated to provide similar 
exposure to the 75mg IV effective dose from 112997.  Additiona lly, a dose of 100mg SC 
will provide plasma concentrations of mepolizumab well above the IC 50for the entire 
dosage interval.  In summary , the 100 mg dose via the SC route has been selected for this 
study  based primaril y on the efficacy and safety profile observed in the MEA112997 
study , and is additionall y supported by [CONTACT_725491]/PD model.
4. SUBJECT SELECTION A ND WITHDRA WAL CRITERI A
4.1. Number of Subjects
In order to qualify  for this study , subjects must have been randomised and received at 
least [ADDRESS_990271] (I P) in the MEA112997 study .  Therefore, the 
number of subjects in this study  will be no greater than 608.
4.2. Inclusion Criteria
Specific information regarding warnings, precautions, contraindications, adverse events, 
andother pertinent information on the [COMPANY_004] investigational product or other study  
treatment that may  impact subject eligibility is provided [GlaxoSmithKline Document 
Number CM2003/[ZIP_CODE]/07 ]. 2017N325880_00
2012N139436_0 [ADDRESS_990272] meet all of the following criteria:
1.Informed Consent: Prior to commencing any  study  related activities, subjects must 
be able and willing to provide written informed consent.
2.MEA112997 Study Participation: Received at least [ADDRESS_990273] during the MEA112997 trial.
3.MEA112997 Treatment Assignment: If the subject received mepolizumab, they  
must have had a positive risk: benefit ratio in the opi[INVESTIGATOR_871].
4.Current Anti -Asthma Therapy: Asthma is currently  being treated with a controller 
medication and the subject has been on a controller medication for the past 12 weeks. 
Subjects will be expected to continue controller therap y for the duration of the study.
5.Male or Eligible Female Subjects:
Tobe eligible for entry  into the study , females of childbearing potential must 
commit to consistent and correct use of an acceptable method of birth control 
(Appendix 2 ) for the duration of the trial and for [ADDRESS_990274] is required of all females. at the initial Screening Visit 
(Visit 1).  I n addition, a urine pregnancy  test will be performed for all females prior 
to Visit 2, during each scheduled study  visit prior to the injection of investigational 
product, and during the Follow -up Visit. 
French subjects: In [LOCATION_009], a subject will be eligible for inclusion in this study onl y if 
either affiliated to or a beneficiary  of a social security  category .
4.3. Exclusion Criteria
Deviations from exclusion criteria are not allowed because they  can potentially  
jeopardize the scientific integrit y of the study, regulatory acceptability or subject safet y. 
Therefore, adherence to the criteria as specified in the protocol is essen tial. 
Subjects meeting an y of the following criteria must not be enrolled in the study :
1.Immunogenicity: Positive neutralizing antibody  status based on the last sample 
obtained during the MEA112997 study .
2.Hypersensitivity: Report of a hy persensitivity  reac tion assessed as related to 
mepolizumab that led to patient withdrawal. Subjects who experienced a localized 
injection -site reaction do not need to be excluded.
3.Health Status: Clinically significant change in health status since completing 
participation i n the MEA112997 trial which in the opi[INVESTIGATOR_725479] . 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
204.Cardiovascular: Subjects who have severe or clinically  significant cardiovascular 
disease uncontrolled with standard treatment. Including but not limited to:
known ejection fraction of <30% OR
severe heart failure meeting [LOCATION_001] Heart Association Class I V (see Appendix 
6) classification OR
hospi[INVESTIGATOR_561879] 12 months prior to Vi sit 1 for severe heart failure meeting New 
York Heart Association Class III (see Appendix 6 ) OR
angina diagnosed less than 3 months prior to Visit 1 or at Visit 1
5.Malignancy: A current malignancy or previous history  of cancer in remission for 
less than 12 months prior to screening (Subjects that had localized carcinoma of the 
skin which was resected for cure will not be excluded). [ Note for South Korea: 
Korean subjects with a diagnosis of malignancy  within 5years are e xcluded]
6.Prior SAE: For those subjects who had a a SAE in MEA112997 that was assessed 
as possibly  related to mepolizumab by  [CONTACT_093]
7.Pregnancy: Subjects who are pregnant or breastfeeding. Subjects should not be 
enrolled if they  plan to become pregn ant during the time of study  participation.
8.ECG: Screening ECG which has a clinicall y significant abnormality or which shows 
QTcF > 450msec or QTcF >480msec for subjects with Bundle Branch Block.
9.Xolair: Received Xolair (omalizumab) within the past 130 day s
10.Clinical trial: Participated in a clinical trial within the past [ADDRESS_990275] received 
investigational medication within five terminal half -lives of Screen Visit, whichever 
is longer.
11.Smoking status : Current smokers
4.4. Visit 2 Criteria
Subjects should be excluded if an y of the following are met:
1.Liver Function: Liver Function Tests at screening that meet an y of the following: 
ALT ≥[ADDRESS_990276] (upper limit of normal) 
AST ≥2 x UL N 
Alk Phos ≥2 x UL N 
Bilirubin >1.5 x UL N (isolated bilirubin >1.5x ULN is acceptable if bilirubin is 
fractionated and direct bilirubin is <35%)
2.Hepatitis Status: Positive Hepatitis B Surface Antigen (HBsAg) screen at Visit 1
3.ECG Over -read: Clinically  significant abnormality  identified during the central 
over-read 
4.Parasitic Infection: Subjects with a known parasitic infection within 6 months of 
Visit 2. 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
214.5. Withdrawal Criteria
Subjects may  be withdrawn from stu dy treatment at any time by  [CONTACT_646021] . Reasons for withdrawal 
can include: an adverse event, lost to follow -up, protocol violation, lack of efficacy , 
sponsor terminated study, no n-compliance, pregnancy , abnormal liver function test, 
abnormal laboratory  results, or for an y other reason. L iver chemistry  stoppi[INVESTIGATOR_725480] 6.3.2. In addition, QTc discontinuation crit eria are listed below:
QTc(F)>500 msec or uncorrected QT>600 msec
Bundle branch block: QTc(F)>530 msec ( Note: QTc(F)>500 msec for Korean 
subjects)
Change from baseline: QTc > 60msec
[Based on average QTc(F) value of triplicate ECGs. If an ECG demonstrates a 
prolonged QT interval, obtain 2 more ECGs over a brief period, and then use the 
averaged QTc(F)values of the 3 ECGs to determine whether the patients should be 
discontinued from the study ].
Subjects are free to discontinue participation in the study  at anytime. Every  effort should 
be made to have the subject return for a Follow -up visit [ADDRESS_990277] after 3 documented attempts via 2 different methods (phone, text, 
e-mail, certified letter, etc). These efforts should be documented in the clinic notes at the 
site.
Subjects may  also be withdrawn from this study  if mepolizumab becomes commercially  
available in the respective country , marketing of mepolizumab is no longer being sought 
in the respective country , or upon decision of the sponsor to discontinue further 
development of mepolizumab.
The primary  reason for withdrawal will be recorded in the eCRF and an y data collected 
up until the point of withdrawal will be used in the data anal yses. 
4.6. Screening/Run -in Failures
Subjects will be assigned a study  number at the time of signing the Informed Consent 
Form.  Those subjects that complete at least one additional Visit 1 (Screen Visit) 
procedure, but do not enter the run -in period will be designated as screen failures.
Those subjects that en ter the Run- in period, but do not receive a dose of mepolizumab, 
will be designated as run -in failures.
Information to be collected for screen failure and run-in failures will be detailed in the 
eCRF completion guidelines. 2017N325880_00
2012N139436_0 [ADDRESS_990278]
Mepolizumab (SB -240563) is a fully  humanised IgG antibody  (IgG1, kappa) with human 
heav y and light chain frameworks.  Mepolizumab will be provided as a l yophilised cake 
in sterile vials for individual use.  The vial will be reconstituted with Steri le Water for 
Injection, just prior to use.  Further details of dose preparation and administration can be 
found in the Clinical I nvestigator’s Brochure (CIB), and the Study  Procedures Manual 
(SPM). 
The contents of the label will be in accordance with all applicable regulatory 
requirements.
Under normal conditions of handling and administration, investigational product is not 
expected to pose significant safet y risks to site staff.  Take adequate precautions to avoid 
direct ey e or skin contact [CONTACT_725492]. Notify  the monitor of 
any unintentional occupational exposure.  A Material Safet y Data Sheet (MSDS) 
describing the occupational hazards and recommended handling precautions will be 
provided to site staff if required by  [CONTACT_1769] s or will otherwise be available from [COMPANY_004] 
upon request.
Investigational product must be stored in a secure area under the appropriate phy sical 
conditions for the product.  Access to and administration of the investigational product 
will be limited to the investigator’s authorized site staff.  Mepolizumab must be stored 
under the appropriate physical conditions which includes storage in a refrigerator or at a 
temperature of 2 -8C and protected from light.  Maintenance of a temperature log 
(manual or automate d) is required. Investigational product must be dispensed or 
administered only  to subjects enrolled in the study and in accordance with the protocol.
5.2. Dosage and A dministration
Prior to administration, each vial of mepolizumab will need to be reconstituted and 
swirled gently  to enable complete dissolution of the product.  Detailed instructions can be 
found within the SPM.
Once the mepolizumab vial is reconstituted, [ADDRESS_990279] 3 doses, safet y monitoring will be 
according to local site policy .  Such monitoring will include general safet y monitoring 
including monitoring for both sy stemic (ie, allergic/IgE -mediated and non- allergic) and 
local injection -site reactions . Trained rescue personnel and rescue medications/equipment 
must be available for use at all times. (See Section 6.3.1) 2017N325880_00
2012N139436_0 [ADDRESS_990280] A ccountability
In accordance with local regulatory  requirements, the investigator, designated site staff, 
or head of the medical institution (where applicable) must document the amount of 
investigational product dispensed and/or administered to study  subjects and the amount 
received from and returned to [COMPANY_004], when applicable.  Product accountability  records 
must be maintained throughout the course of the study .
5.6. Treatment Compliance
All doses administered within the study  unit will be administered under the supervision 
of the Investigator, designee or stud y nurses.
Drug dispensing/accountability  logs will be maintained by  a member of the study  team 
designated b y the Investigator.
5.7. Concomitant Medications and Non -Drug Therapi[INVESTIGATOR_014]
5.7.1. Permitt ed Medications and Non- Drug Therapi[INVESTIGATOR_725481] (eCRF). The minimum requirement is that drug name [CONTACT_699902]. However, for corticosteroids, the dose must be 
recorded as well as well as an y dose changes.
Additional medications to treat asthma are permitted, as are medications to treat other 
disease states, with the exception of those listed as prohibited.  Ox ygen and Continuous
Positive Airway  Pressure (CPAP) are permitted for the treatment of obstructive sleep 
apnea.
5.7.2. Prohibited Medications and Non- Drug Therapi[INVESTIGATOR_725482] : 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
24Table 1 Medications not allo wed prior to the screening visit and throughout 
the study
MedicationWashout Time
Prior to Screening Visit
Investigational drugs 1 month or 5 half -lives whichever is 
longer
Omalizumab [Xolair] 130 day s
Other monoclonal antibodies 5 half -lives
Experimental anti -inflammatory drugs (non biologicals) 3 months
Immunosuppressive medications such as those listed below (not all inclusive)
Corticosteroids intramuscular, long -acting depot if 
used to treat a condition other than asthma3 months
Methotrexate, troleandomycin, cyclosporin, 
azathioprine 1 month
Oral gold 3 months
Chemotherapy used for conditions other than 
asthma12 months
Regular systemic (oral or parenteral) corticosteroids 
for the treatmen t of conditions other than asthma3 months
Additionally , Bronchial Thermoplasty  and Radiotherapy  are excluded for [ADDRESS_990281]’s medical condition whether or not [COMPANY_004] is providing specific 
post study  treatment. At the end of the study , subject s should be prescribed appropriate 
alternative asthma therapy if needed and as determined by  [CONTACT_725493].
5.9. Treatment of Study  Treatment Overdose
The dose of mepolizumab considered to be an overdose has not been defined. There are 
no known antidot es and [COMPANY_004] does not recommend a specific treatment in the event of a 
suspected overdose. The investigator will use clinical judgement in treating the sy mptoms 
of a suspected overdose. 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
256. STUDY A SSESSMENTS A ND PROCEDURES
Table [ADDRESS_990282] Year
Procedures Screen Baseline Treatment (window is 1 week) Follow -up
4weeks
visit [ADDRESS_990283] completion 
of  MEA 112997X
Inclusion/Exclusion Criteria X X
Safety Assessments
Concomitant Me dication X X X X X X X X X X X X X X
Physical Examination X X
Vital Signs X X X X X X X X X X X X X X X
12-lead ECG X X X X
Adverse Events X X X X X X X X X X X X X X X
Serious Adverse Events X X X X X X X X X X X X X X X
Laboratory Assessments4
Haematology X X X X X X X
Chemistry plus lipoproteins5 X X
Chemistry X X X X X X X
Pregnancy Test 1 S U U U U U U U U U U U U U U
Immunogenicity X X * X * * * * * X X
HbsAg and hepatitis C antibody2 X
Efficacy Assessments 
 
 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
26Procedures Screen Baseline Treatment (window is 1 week) Follow -up
4weeks
visit [ADDRESS_990284]
injection6 Week of study -4 to -1 0 4 8 12 16 20 24 28 32 36 40 44 48
Exacerbation review X X X X X X X X X X X X X X 
Asthma Control Questionnaire -5 X X X X X X
Spi[INVESTIGATOR_038] - X   X X X
Worksheets/IP/eCRF
Administer Investigational 
Product.X X X X X X X X X X X X X
Dispense paper worksheet X X X X X X X X X X X X X X
Collect paper worksheet X X X X X X X X X X X X X X
Phone IVRS X X X X X X X X X X X X X X X
Complete eCRF X X X X X X X X X X X X X X X
1. Pregnancy test (all females) U = Urine,  S= Serum
2. Hepatitis B Surface Antigen and Hepatitis C antibody ( if Hepatitis C antibody positive, a hepatitis C confirmatory test shoul d be automatically performed to confirm the result)
3. Parasitic screening only in countries with a high -risk or for subjects who have visited high -risk countries in the past [ADDRESS_990285] has not fasted, may return the next business day to obt ain this sample
6. Follow -up visit window is 1week
* Take additional immunogenicity sample immediately prior to first dose with 100mg vial and prior to the second dose with the 100mg vial. Maximum of 2 additional samples 
 
 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
27Table 3 Time and Events Table for A dditional Years
Procedures Treatment subsequent years
(repeat 48 week cycle for each subsequent year)Follow -up
4weeks
visit [ADDRESS_990286]
injection4Week of study ( 1 week) 52 56 60 64 68 72 76 80 84 88 92 96 100
Safety Assessments
Assess Risk: Benefit ratio X
Concomitant Medication X X X X X X X X X X X X X
Physical Examination X X
Vital Signs X X X X X X X X X X X X X X
12-lead ECG X X X
Adverse Events/SAEs X X X X X X X X X X X X X X
Laboratory Assessments2
Haematology X X X
Chemistry plus lipopr oteins3 X
Chemistry X X
Pregnancy Test1 U U U U U U U U U U U U U U
Immunogenicity * * * * * X * * * * * X X
Efficacy Assessments
Exacerbation review (worksheet) X X X X X X X X X X X X X X
Asthma Control Questionnaire X X X X X
Spi[INVESTIGATOR_038] - X X
IP/eCRF/Worksheets
Administer IP X X X X X X X X X X X X X
Dispense paper diary card X X X X X X X X X X X X X
Collect paper diary card X X X X X X X X X X X X X X
Phone IVRS X X X X X X    X X X X X X X
Complete eCRF X X X X X X    X X X X X X X X
1. Pregnancy test (all females) U = Urine
2. All laboratory tests are to be c ompleted prior to dosing
3. Subject must be in the fasting state. If subject has not fasted, may return the next business day to obtain this sample
4. Follow -up visit window is 1weeks
* Take additional immunogenicity sample immediately prior to first dose wit h 100mg vial and prior to the second dose with the 100mg vial. Maximum of 2 additional samples 
 
 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
286.1. Critical Baseline A ssessments
Screening and baseline assessments at Visit 1 or Visit 2 (Week 0) will comprise the 
following:
Demographic information including date of birth
Update medical history
Cardiovascular medical history /risk factors will be assessed at screening. This 
assessment must include a review of the subject responses to the cardiovascular 
assessment questions (See Appendix 5 ) and height, weight, blood pressure, 
medical conditions, and family  history  of premature cardiovascular disease.
Therap y history , including review of use of biologics.
Review of immunogenicity  status from MEA112997.
Physical examination (in cluding nasal exam to check for the presence or 
absence of nasal pol yps.)
Pulmonary  function tests and assessment. 
Assessment of Inclusion/Exclusion criteria. (At Visit 2, will need to review the 
results of laboratory  tests from Visit 1 and the ECG over -read results)
Asthma Control Questionnaire (ACQ -5). Further details are provided in 
Section [IP_ADDRESS]
Vital signs (further details are provided in Section [IP_ADDRESS])
12-lead ECG (further details are provided in Section [IP_ADDRESS])
Blood sampling for the following:
oClinical chemistry
oClinical chemistry  plus lipoproteins at Visit 2 (subject must fast)
oHaematology
oImmunogenicit y
oPregnancy  test (all females)
oHbsAg and hepatitis C antibody
Parasitic screening (onl y in countries with a high -risk or in subjects who have 
visited a country  with a high-risk) 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
296.2. Efficacy
6.2.1. Efficacy  Endpoints
Annualized rate of exacerbations
Asthma Control Questionnaire score
FEV 1measured b y clinic spi[INVESTIGATOR_038]
[IP_ADDRESS]. Exacerbations
Exacerbations will be defined as worsening of asthma which requires use of sy stemic 
corticosteroids1and/or hospi[INVESTIGATOR_31739]/or Emergency  Department (ED) visits.
1For all subjects, IV. or oral steroid (e.g., prednisone) for at least [ADDRESS_990287] 3 days is required. 
[IP_ADDRESS]. Pulmonary  Function Testing
Spi[INVESTIGATOR_725483], using the site’s own equipment at the visits specified in the 
Time and Events schedule ( Table 2 and Table 3 ).  The spi[INVESTIGATOR_725484] c Society  standards and produce a printout of all data generated, which should be 
stored in the subject’s notes.  The spi[INVESTIGATOR_725485]’s instructions and a calibration log maintained. Spi[INVESTIGATOR_725486] 1 hour of the baseline assessment.  Subjects should try  to withhold 
short -acting beta -2-agonists (SABAs) for ≥6 hours and LABAs for  12 hours prior to 
clinic visit, if possible. Assessments to be recorded will include FEV 1and FVC.
[IP_ADDRESS]. Asthma Control Questionnaire -5 (ACQ)
The ACQ -[ADDRESS_990288]’ asthma control that can be quickly  and easily  completed [ Juniper , 2005].  The 
questions are des igned to be self -completed by  [CONTACT_423].  The five questions enquire 
about the frequency  and/or severit y of s ymptoms (nocturnal awakening on waking in the 
morning, activity  limitation, and shortness of breath, wheeze).  The response options for 
all these questions consist of a zero (no impairment/limitation) to six (total impairment/ 
limitation) scale.
The subject should be given a quiet area in which to complete the paper questionnaire. 
The investigator should ask the subject to complete the questions as accurately  as 
possible.  I f the subject requests help or clarification with any  of the questions, he/she 
will be asked to re -read the instructions and give the answer that best reflects how he/she 
felt over the previous week.  The subject should be reassu red that there are no right or 
wrong answers.  The investigator should not provide the subject with an y answer or 
attempt to interpret an y portion of a question.  The site -staff will transfer the subject 
responses on paper into the eCRF. 2017N325880_00
2012N139436_0 [ADDRESS_990289]’s response.  Adequate time 
should be allowed to complete all items on the ACQ.
6.3. Safet y
6.3.1. Safety  Endpoints
Adverse Events, including both s ystemic (ie, allergic/IgE -mediated and non -allergic) 
and local site reactions.
NOTE: Hy persensitivity  reactions (ie, allergic or IgE- mediated reactions) will be 
monitored using the diagnostic criteria for anaph ylaxis as outlined by  [CONTACT_941] 2006 Joint 
NIAI D/FAAN Second Sy mposium on Anaphy laxis [ Sampson, 2006] ( Append ix 4).  
Information will be also collected to assess localised site reactions.
12-lead ECG to derive the following endpoints:
Mean change from baseline in the QTc(F) (QT interval corrected b y Fridericia's 
method)
Mean change from baseline in QTc(B) (QT interval corrected b y Bazett's 
method)
Maximum change from baseline for QTc(F) and QTc(B).
Clinical L aboratory  parameters
Vital signs
6.3.2. Liver chemistry  stoppi[INVESTIGATOR_23913] -IV liver chemistry  stoppi[INVESTIGATOR_3418] 1- 5 are defined below and in Appendix 3 :
1.ALT 3xULN and bilirubin 2xUL N (>35% direct bilirubin) (or ALT  3xULN 
and INR>1.5, if INR measured)
NOTE: if serum bilirubin fractionation is not immediatel y available, withdraw study 
drug for that subject if ALT 3xULN and bilirubin 2xUL N. Serum bilirubin 
fractionation should be performed if testing is available. If testing is unavailable, 
record presence of detectable urinary bilirubin on dipstick , indicating direct 
bilirubin elevations and suggesting liver injury .
2.ALT 8xULN.
3.ALT 5xULN but <[ADDRESS_990290] persists for 2 weeks
4.ALT   3xULN if associated with sy mptoms (new or worsening) believed to be 
related to  hepatitis (such as fatigue, naus ea, vomiting, right upper quadrant pain or 
tenderness, or jaundice) or hy persensitivity  (such as fever, rash or eosinophilia).
5.ALT 5xULN but <[ADDRESS_990291] and cannot be monitored weekl y for 2 weeks 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
31When any of the liver chemistry stoppi[INVESTIGATOR_3418] 1- 5 is met, do the following:
Immediately withdraw investigational product for that subject
Report the event to [COMPANY_004] within 24 hours of learning its occurrence
Complete the liver event CRF and SAE data collection tool if the event also meets 
the criteria for an SAE. A ll events of ALT 3xULN andbilirubin 2xULN (>35% 
direct) (or ALT 3xULN and INR>1.5, if INR measured); INR measurement is not 
required and the threshold value stated will not apply  to patients receiving 
anticoagulants), termed ‘Hy ’s Law’, must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) . 
NOTE: if serum bilirubin fractionation is not immediatel y available, withdraw study 
drug for that subject if ALT 3xULN andbilirubin 2xUL N. Serum bilirubin 
fractionation should be performed if testing is available. If testing is unavailable, 
record presence of detectable urinary bilirubin on dipstick , indicating direct 
bilirubin elevations and suggesting liver injury .
Complete the liver imaging and/or liver biopsy  CRFs if these test s are performed
Perform liver event follow up assessments, and monitor the subject until liver 
chemistries resolve, stabilize, or return to baseline values as described below. 
Withdraw the subject from the study  after completion of the liver chemistry 
monitoring (unless further safet y follow up is required)  
Do not re -challenge with investigational product.
In addition, for criterion 1: 
Make every  reasonable attempt to have subjects return to clinic within 24 hours for 
repeat liver chemistries, liver eve nt follow up assessments (see below), and close 
monitoring
A specialist or hepatology consultation is recommended
Monitor subjects twice weekl y until liver chemistries (ALT, AST, alkaline 
phosphatase, bilirubin) resolve, stabilize or return to within basel ine values
For criteria 2, 3, 4 and 5:
Make every  reasonable attempt to have subjects return to clinic within 24-72 hrs for 
repeat liver chemistries and liver event follow up assessments (see below)
Monitor subjects weekl y until liver chemistries (ALT, AST , alkaline phosphatase, 
bilirubin) resolve, stabilize or return to within baseline values; criterion 5 subjects 
should be monitored as frequently  as possible.
Subjects with AL T 5xULN and <8xULN which exhibit a decrease to ALT x 3xULN, 
but <5xUL N and bilir ubin <2xUL N without hepatitis sy mptoms or rash, and who can be 
monitored weekl y for 4 weeks:
Notify  the [COMPANY_004] medical monitor within [ADDRESS_990292] safet y 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
32Can continue investigational product 
Must return weekl y for repeat liver chemistries (AL T, AST, alkaline phosphatase, 
bilirubin) until they  resolve, stabilize or return to within baseline 
If at an y time these subjects meet the liver chemistry  stoppi[INVESTIGATOR_3418], proceed as 
described above
If, after 4 weeks of mon itoring, ALT <3xUL N and bilirubin <2xUL N, monitor 
subjects twice monthly  until liver chemistries normalize or return to within baseline 
values. 
For criteria 1 -5, make every  attempt to carry  out the liver event follow up assessments
described below:
Viral hepatitis serology  including:
Hepatitis A IgM antibody;
Hepatitis B surface antigen and Hepatitis B Core Antibody  (IgM); 
Hepatitis C RNA; 
Cytomegalovirus IgM antibody;  
Epstein- Barr viral capsid antigen IgM antibod y (or if unavailable, obtain 
heterophil e antibod y or monospot testing);  
Hepatitis E IgM antibody 
Blood sample for PK analy sis, obtained within [ADDRESS_990293] the 
date/time of the PK blood sample draw and the date/time of the last dose of 
investigational product prior to blood sample draw on the CRF. If the date or time of 
the last dose is unclear, provide the subject’s best approximation. I f the date/time of 
the last dose cannot be approximated OR a PK sample cannot be collected in the 
time period indicated above, do not obtain a PK sample. I nstructions for sample 
handling and shippi[INVESTIGATOR_23915]. 
Serum creatine phosphokinase (CPK) and lactate dehy drogenase (LDH).
Fractionate bilirubin, if total bilirubin 2xUL N
Obtain complete blood count with differential to assess eosino philia
Record the appearance or worsening of clinical s ymptoms of hepatitis or 
hypersensitivity , such as fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever rash or eosinophilia as relevant on the AE report form
Record use of concomit ant medications, acetaminophen, herbal remedies, other over 
the counter medications, or putative hepatotoxins, on the concomitant medications 
report form.
Record alcohol use on the liver event alcohol intake case report form 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
33The following are required for subjects with ALT  3xUL N and bilirubin  2xULN (>35% 
direct) but are optional for other abnormal liver chemistries:
Anti- nuclear antibody , anti -smooth muscle antibody , and Ty pe 1 anti -liver kidney  
microsomal antibodies.
Serum acetaminophen adduct HPL C assay (quantifies potential acetaminophen 
contribution to liver injury  in subjects with definite or likely acetaminophen use in 
the preceding week .  
Only  in those with underly ing chronic hepatitis B at study  entry  (identified by  
[CONTACT_23977] B surface an tigen):  quantitative hepatitis B DNA and hepatitis 
delta antibody .  NOTE :  if hepatitis delta antibody assay  cannot be performed,, it can 
be replaced with a PCR of hepatitis D RNA virus (where needed) –as outlined in: 
http://www.ncbi.nlm.nih.gov/pmc/arti cles/PMC1153793/
Liver imaging (ultrasound, magnetic resonance, or computerized tomography ) to 
evaluate liver disease.
6.3.3. Adverse Events
Subject will be issued a paper worksheet to record adverse events during the study
The investigator or site staff will be responsible for detecting, documenting and reporting 
events that meet the definition of an AE or SAE.
[IP_ADDRESS]. Definition of an AE
Any untoward medical occurrence in a patient or clinical investigation subject, 
temporally  associated with the use of a medicinal prod uct, whether or not considered 
related to the medicinal product.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a medicinal product.  For marketed medicinal products, this 
also includes failure to produce expected benefits (i.e., lack of efficacy ), abuse or misuse.
Events meeting the definition of an AE include:
Exacerbation of a chronic or intermittent pre- existing condition including either an 
increase in frequency  and/or intensity  of the condition
New conditions detected or diagnosed after stud y treatment administration even 
though it may  have been present prior to the start of the study
Signs, sy mptoms, or the clini cal sequelae of a suspected interaction
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE) unless this is an intentional overdose taken with possible suicidal/self -
harming intent.  This should be reported regardless of sequelae . 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
34“Lack of efficacy ” or “failure of expected pharmacological action” per se will not be 
reported as an AE or SAE. However, the signs and sy mptoms and/or clinical se quelae 
resulting from lack of efficacy  will be reported if they  fulfill the definition of an AE or 
SAE.  
Events that do not meet the definition of an AE include:
Medical or surgical procedure (e.g., endoscop y, appendectom y); the condition that 
leads to th e procedure is an AE
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307])
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study  that do not worsen
The disease/disorder being studied, or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
condition
[IP_ADDRESS]. Definition of a SA E
A serious adverse event is any  untoward medical occurrence that, at any  dose:
a.Results in death
b.Is life -threatening
NOTE:  The term 'life -threatening' in the definition of 'serious' refers to an event in 
which the subject was at risk of death at the time of the event.  It does not refer to an 
event, which h ypothetically  might have caused death, if it were more severe.
c.Requires hospi[INVESTIGATOR_23916]:  In general, hospi[INVESTIGATOR_5184] 
(usually  involving at leas t an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or out -patient setting.  Complications that occur during hospi[INVESTIGATOR_23918].  If a complication prolongs hospi[INVESTIGATOR_23919], 
the event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen 
from baseline is not considered an AE. 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
35d.Results in disability /incapacity , or
NOTE:  The term disability  means a substantial disruption of a person’s ability  to 
conduct normal life functions.  This definition is not intended to inclu de experiences 
of relativel y minor medical significance such as uncomplicated headache, nausea, 
vomiting, diarrhea, influenza, and accidental trauma (e.g. sprained ankle) which may  
interfere or prevent everyday  life functions but do not constitute a substa ntial 
disruption.
e.Is a congenital anomal y/birth defect
f.Medical or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_288599].  These should also be considered 
serious.  Examples of such events are invas ive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of 
drug dependency  or drug abuse.
g.All events of possible drug -induced liver injury  with hy perbilirubinaemia defined as 
ALT 3xULN andbilirubin 2xUL N (>35% direct) (or ALT 3xUL N and 
INR>1.5, if INR measured) termed ‘Hy ’s Law’ events ( INR measurement is not 
required and the threshold value stated will not apply  to patients receiving 
anticoagulants).
NOTE: bilirubin fractionation is performed if testing is available. If testing is 
unavailable, record presence of detectable urinary  bilirubin on dipstick indicating 
direct bilirubin elevations and suggesting liver injury . If testing is unavailable and a 
subject meets the criterion of total bilirubin 2xULN, then the event is still reported 
as an SAE. If INR is obtained, include values on the SAE form. INR elevations >1.[ADDRESS_990294] results (haematology , clinical chemistry , or urinaly sis) or 
other safet y assessments (e.g., ECGs, radiological scans, vital signs measurements), 
including those that wors en from baseline, and felt to be clinically  significant in the 
medical and scientific judgement of the investigator are to be recorded as AEs or SAEs.
However, an y clinicall y significant safet y assessments that are associated with the 
underly ing disease, u nless judged b y the investigator to be more severe than expected for 
the subject’s condition, are notto be reported as AEs or SAEs. 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
366.3.5. Cardiovascular Events
Investigators will be required to fill out event specific pages in the eCRF for the 
following AEs and SAEs:  
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thrombosis
Deep Venous Thrombosis
Revascularization
Card iovascular events information should be recorded on the corresponding eCRF pages 
within one week of when the AE/SAE(s) are first reported. Please refer to Section 6.3.9
for timelines for reporting AE/SAEs.
6.3.6. Death Events
In addition, all deaths will require completion of a specific death data collection page in 
the eCRF.  The death data collection page in the eCRF includes questions regarding 
cardiovascular (including sudden cardiac death) and non-cardiovascular de ath.
Death information should be recorded on the death eCRF page within one week of when 
the death is first reported.
Please refer to Section 6.3.[ADDRESS_990295] be followed up to 
determine outcome (including premature termination) and status of mother and child.  
Pregnancy  complications and elective terminations for medical reasons must be reported 
as an AE or SAE.  Spontaneous abortions must be reported as an SAE.
Any SAE occurring in association with a pregnancy, brought to the investigator’s 
attention after the subject has completed the stud y and considered b y the investigator as 
possibly  related to the study  treatment, must be promptly  reported to [COMPANY_004]. 2017N325880_00
2012N139436_0 [ADDRESS_990296] (Visit 2) and until the 
follow up visit ( [ADDRESS_990297] injection).
SAEs will be collected over the same time period as stated above for AEs. However, any  
SAEs assessed as related to study  participation (e.g., study  treatment, protocol -mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] concomitant 
medication, will be recorded from the time a subject consents to participate in the study  
up to and including an y follow up contact. All SAEs will be reported to [COMPANY_004] within 24 
hours, as indicated in Section 6.3.9.
6.3.9. Prompt Reporting of Serious A dverse Events and Other Events 
to [COMPANY_004]
SAEs, pregnancies, medical device incidents, and liver function abnormalities meeting 
pre-defined criteria will be reported promptly  by [CONTACT_725494]. 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
38Initial Reports Follow -up Information on a Previous 
Report
Type of Event Time Frame Documents Time Frame Documents
All SAEs 24 hours “SAE” data 
collection tool24 hours Updated “SAE” 
data collection tool
“CV events” and/or 
“death” data 
collection tool(
Pregnancy 2 weeks “Pregnancy 
Notification Form”2 weeks “Pregnancy Follow -up 
Form”
Liver chemistry abnormal ities for Phase I to IV:
ALT 3xULN and
Bilirubin 2xULN (>35% 
direct) (or ALT 3xULN 
andINR>1.5, if INR 
measured)124 hours2 “SAE” data 
collection tool.  
“Liver Event CRF” 
and “Liver Imaging” 
and/or “Liver 
Biopsy” CRFs, if 
applicable324 hours Updated “SAE” data 
collection tool/“Liver 
Event” Documents3
Remaining liver chemistry abnormalities Phase III to IV:
ALT 8xULN; 
ALT 3xULN with 
hepatitis or rash or 
3xULN and <5xULN 
that persists 4 weeks24 hours2 “Liver Event” 
Documents (defined 
above)324 hours Updated “Liver Event” 
Documents3
ALT 5xULN plus 
bilirubin <2xULN24 hours2 “Liver Event” 
Documents (defined 
above) do not need 
completing unless 
elevations persist 
for [ADDRESS_990298] cannot be 
monitored weekly 
for 2 weeks324 hours Updated “Liver Event” 
Documents, if 
applicable3
ALT 5xULN and 
bilirubin <2xULN that 
persists 2 weeks24 hours2 “Liver Event” 
Documents (defined 
above) 324 hours Updated “Liver Event” 
Documents3
ALT 3xULN and <5x 
ULN and bilirubin 
<2xULN24 hours2 “Liver Event” 
Documents (defined 
above) do not need 
completing unless 
elevations persist 
for [ADDRESS_990299] cannot be 
monitored weekly 
for 4 weeks324 hours Updated “Liver Event” 
Documents, if 
applicable3
1.INR measurement is not required; if measured, the threshold value stated will not appl y to patients 
receiving anticoagulants.
2.[COMPANY_004] must be contact[CONTACT_23980]
3.Liver Event Documents (i.e., “Liver Event CRF” and “Liver Imaging CRF” and/or “Liver Biopsy CRF”, as 
applicable) should be comple ted as soon as possible. 2017N325880_00
2012N139436_0 [ADDRESS_990300]- study  AEs/SAEs are provided in the SPM.
Procedures for documenting, transmitting and follow -up of medical device incidents 
along with the regulatory reporting requirements for medical devices are provided in the 
SPM.
[IP_ADDRESS]. Regulatory  reporting requirements for SA Es
Prompt notification of SAEs by  [CONTACT_941] i nvestigator to [COMPANY_004] is essential so that legal 
obligations and ethical responsibilities towards the safet y of subjects are met.
[COMPANY_004] has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  [COMPANY_004] will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authorit y, Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC) and investigators.
Investigat or safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and [COMPANY_004] policy  and are forwarded 
to investigators as necessary .
An investigator who receives an investigator safety report describi ng a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requirements.
6.3.10. Other Safety  Outcomes
[IP_ADDRESS]. Vital Signs
Sitting pulse rate and blood pressure measurements will be performed b y the investigator 
or qualified site staff, as outlined in Time and Events Table (see Table 2and Table 3). 
Measurements will be done pre -injection with the subject sitting, having rested in this 
position for at least 5 minutes before each reading.  They  will be taken before 
measurement of an y clinic lung function tests or ECGs at the specified time point.
At the Screen visit, heigh t and weight will also be measured.
[IP_ADDRESS]. Twelve-lead electrocardiogram
Twelve -lead ECGs will be performed at the visits specified in the Time and Events Table 
(see Table 2and Table 3).
Electrocardiogram measurements will be made after the subject has rested in the supi[INVESTIGATOR_31774] [ADDRESS_990301] paper speed of 25mm/sec and 
gain of 10m m/mV, with a lead II rh ythm strip. There will be electronic capture and 
storage of the data b y a validated method, with subsequent transferral to the central 
laboratory  for manual reading and calculation of the electrocardiographic parameters.  
ECGs will also be taken at the end of the Follow -up period.
Paper traces are required to be maintained at the site with other source documents.
[IP_ADDRESS]. Clinical Laboratory  Parameters
Clinical laboratory  tests will be conducted at the visits specified in the Time and Events 
Table (see Table 2 and Table 3). At the discretion of the Investigator, additional samples 
may be taken for safet y reasons.
All blood samples, which will be taken pre -dosing will be sent to a central laboratory  for 
analysis (details provided in the Study  Procedures Manual).  Standard reference ranges 
will be used.  Full details of the collection and shippi[INVESTIGATOR_725487].  The central 
laboratory  will fax laboratory  results to the I nvestigator and will transmit the results 
electronically  to [COMPANY_004]. 
6.4. Immunogenicity
Blood samples will be collected for the determination of anti- mepolizumab antibodi es, 
just prior to administration of mepolizumab, at the time points identified in the Time and 
Events Table (see Table 2and Table 3). Samples that test positive for anti -mepolizumab 
antibodies will be further tested for the presence of neutralising antibody .
A maximum of two additional anti- mepolizumab antibody  samples will be obtained; one 
immediately  prior to the first dose and the other prior to the second dose with the 100mg 
mepolizumab vial. I f the first or second dose coincides with a visit where an 
immunogenicit y sample is alread y required, it is not necessary to obtain an additional 
sample.
For all subjects, immunogenicity  testing will occur at [ADDRESS_990302] data will be entered into [COMPANY_004] defined electronic case report forms 
(eCRFs), transmitted electronicall y to [COMPANY_004] and combined with data provided from other 
sources in a validated data sy stem.  
Management of clin ical data will be performed in accordance with applicable [COMPANY_004] 
standards and data cleaning procedures to ensure the integrity of the data, e.g., removing 
errors and inconsistencies in the data.  Adverse events and concomitant medications 
terms will be coded using MedDRA and an internal validated medication dictionary , 
[COMPANY_004]Drug.  In all cases, subject initials will not be collected or transmitted to [COMPANY_004] 
according to [COMPANY_004] policy . 2017N325880_00
2012N139436_0 [ADDRESS_990303] been defined for this study.
8.2. Stud y Design Considerations
8.2.1. Sample Size A ssumptions
There is no sample size calculation for this study. The sample size will be determined b y 
the number of available subjects who were randomised into study  MEA112997 and are 
eligible for the current study  based on inclusion and exclusion criteria.
8.2.2. Sample Size Sensitivity
Not applicable.
8.2.3. Sample Size Re -estimation
Not applicable.
8.3. Data Analysis Considerations
All pre -specified analy ses will be described in a full Reporting and Analy sis Plan (RAP) 
which will be finalised prior to database freeze.
8.3.1. Analysis Populations
The All Subjects Enrolled population will comprise all subjects for whom a record exists 
on the database. 
The As Treated population will consist of all subjects who received at least one dose of 
open label mepolizumab.
8.3.2. Analysis Data Sets
All analy ses will be performed using all available data as outlined in the Reporting and 
Analy sis Plan.
8.3.3. Treatment Comparisons
No treatment comparisons will be performed.
[IP_ADDRESS]. Primary  Comparisons of Interest
Not applicable. 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
[IP_ADDRESS]. Other Comparisons of Interest
Not applicable.
8.3.4. Interim A nalysis
Interim anal ysis will be performed as needed in or der to provide open -label safet y data to 
inform the risk -benefit assessment of mepolizumab in severe asthma.
8.3.5. Key Elements of A nalysis Plan
Further detail will be fully described in the RAP.
[IP_ADDRESS]. Efficacy  Analyses
All efficacy  endpoints will be summarised using descriptive statistics. Further details will 
be provided in the RAP.
[IP_ADDRESS]. Safety  Analyses
All safet y endpoints will be summarised using descriptive statistics. Further details will 
be provided in the RAP.
[IP_ADDRESS]. Immunogenicity  Analyses
All immunogenicity  endpoints wil l be summarised using descriptive statistics. The 
number and percentage of subjects with positive neutralizing antibodies before and after 
the introduction of the 100mg mepolizumab vial will be tabulated. Further details will be 
provided in the RAP.
9. STUDY CONDUCT CONSIDERA TIONS
9.1. Posting of Information on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrolment of subjects begins.
9.2. Regulatory  and Ethical Cons iderations, Including the 
Informed Consent Process
Prior to initiation of a study site, [COMPANY_004] will obtain favourable opi[INVESTIGATOR_1649]/approval from the 
appropriate regulatory  agency  to conduct the study in accordance with I CH Good Clinical 
Practice (GCP) and applicab le country -specific regulatory  requirements.
The study  will be conducted in accordance with all applicable regulatory  requirements.
The study  will be conducted in accordance with ICH GCP, all applicable subject privacy  
requirements, and the ethical princip les that are outlined in the Declaration of Helsinki 
2008, including, but not limited to: 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
43Institutional Review Board (IRB)/Independent Ethics Committee (I EC) review and 
favourable opi[INVESTIGATOR_1649]/approval of study  protocol and any  subsequent amendments.
Subject in formed consent.
Investigator reporting requirements.
[COMPANY_004] will provide full details of the above procedures, either verball y, in writing, or both.
Written informed consent must be obtained from each subject prior to participation in the 
study .
9.3. Qualit y Control (Study  Monitoring)
In accordance with applicable regulations, GCP, and [COMPANY_004] procedures, [COMPANY_004] monitors 
will contact [CONTACT_23988], 
study  requirements, and their responsibilities to satis fy regulatory , ethical, and [COMPANY_004] 
requirements.  When reviewing data collection procedures, the discussion will include 
identification, agreement and documentation of data items for which the CRF will serve 
as the source document.
[COMPANY_004] will monitor the study  to ensure that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  other 
study  agreements, GCP, and all applicable regulatory  requirements.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents. 2017N325880_00
2012N139436_0 [ADDRESS_990304] a qualit y assurance assessment and/or audit of the site records, and the regulatory  
agencies may  conduct a regulatory  inspection at any  time during or after completion of 
the study . In the event of an assessment, audit or inspection, the investigato r (and 
institution) must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to 
all relevant documents and to allocate their time and the time of their staff to discuss the 
conduct of the stud y, an y findings/relevant issues and to impl ement any  corrective and/or 
preventative actions to address an y findings/issues identified.
9.5. Stud y and Site Closure
The study  will be considered complete when the last subject completes the last visit. 
Upon completion or termination of the study , the [COMPANY_004] monitor will conduct site closure 
activities with the investigator or site staff (as appropriate), in accordance with applicable 
regulations, GCP, and [COMPANY_004] Standard Operating Procedures.
[COMPANY_004] reserves the right to temporaril y suspend or terminate the stud y at any time for 
reasons including (but not limited to) safety issues, ethical issues, or severe non -
compliance.  If [COMPANY_004] determines that such action is required, [COMPANY_004] will discuss the 
reasons for taking such action with the investigator or head of the medical i nstitution 
(where applicable).  When feasible, [COMPANY_004] will provide advance notice to the investigator 
or head of the medical institution of the impending action.
If a study is suspended or terminated for safety reasons, [COMPANY_004] will promptly inform all 
investigat ors, heads of the medical institutions (where applicable),and/or institutions 
conducting the study .  [COMPANY_004] will also promptly  inform the relevant regulatory  authorities 
of the suspension/termination along with the reasons for such action.  Where required b y 
applicable regulations, the investigator or head of the medical institution must inform the 
IRB/IEC promptly  and provide the reason(s) for the suspension/termination.
9.6. Records Retention
Following closure of the study , the investigator or head of the medical institution (where 
applicable) must maintain all site study records (except for those required by  [CONTACT_24000]) in a safe and secure location.  The records must 
be easil y accessible when needed (e.g., for a [COMPANY_004] audit or reg ulatory  inspection) and 
must be available for review in conjunction with assessment of the facility , supporting 
systems, and relevant site staff.
Where permitted b y local laws/regulations or institutional policy, some or all of the 
records may  be maintaine d in a format other than hard cop y (e.g., microfiche, scanned, 
electronic); however, caution must be exercised before such action is taken.  The 
investigator must ensure that all reproductions are legible and are a true and accurate 
copy  of the original. I n addition, they  must meet accessibility  and retrieval standards, 
including regeneration of a hard cop y, if required.  The investigator must also ensure that 
an acceptable back -up of the reproductions exists and that there is an acceptable quality  
control procedure in place for creating the reproductions. 2017N325880_00
2012N139436_0 [ADDRESS_990305] applicable to a particular site, as dictated b y local 
laws/regulations, [COMPANY_004] standard operating procedures, and/or institutional requirements.
The investigator must notify  [COMPANY_004] of any  changes in the archival arrangements, including, 
but not limited to arc hival of records at an off -site facility  or transfer of ownership of the 
records in the event that the investigator is no longer associated with the site.
9.7. Provision of Study  Results to Investigators, Posting of 
Information on Publicly  Available Clinical Tr ials Registers 
and Publication
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified for the approval of the clinical study  report.  The investigator will be provided 
reasonable access to statistical tables, fig ures, and relevant reports and will have the 
opportunity  to review the complete study  results at a [COMPANY_004] site or other mutually -
agreeable location.
[COMPANY_004] will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encour aged to share the summary  results with the study  subjects, as 
appropriate.
[COMPANY_004] aims to post a results summary  to the [COMPANY_004] Clinical Study  Register and other 
publicly  available registers no later than [ADDRESS_990306]’s last visit (L SLV) 
[this applies to each data anal ysis phase for studies with multiple phases, e.g., primary  
analysis, follow up anal ysis etc]. I n addition, the aim is to submit a manuscript to a peer-
reviewed journal for publication within 18 months of L SLV. [COMPANY_004] also aims to publ ish 
the full study  protocol on the [COMPANY_004] Clinical Study  Register at the time the results of the 
study  are published as a manuscript in the scientific literature. 
When manuscript publication in a peer -reviewed journal is not feasible, further study  
informati on will be posted to the [COMPANY_004] Clinical Study Register to supplement the results 
summary . 
9.8. Independent Data Monitoring Committee (IDMC)
An IDMC will be utilized in this study  to ensure external objective medical and/or 
statistical review of safety  and/or eff icacy  issues in order to protect the ethical and safet y 
interests of subjects and to protect the scientific validity  of the study .  The schedule of 
any planned interim analy sis and the anal ysis plan for IDMC review is described in the 
charter, which is ava ilable upon request. 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
4610. REFERENCES
American Heart Association.  Classes of Heart Failure.  Available at: 
http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes -
of-Heart -Failure_UCM_306328_Article.jsp.  Accessed [ADDRESS_990307] 2012.
Bateman ED, Boushey  HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE. 
Can guideline -defined asthma control be achieved? The Gaining Optimal Asthma 
ControL  study . Am J Respir Crit Care Med 2004;170:836-844.
Clutterbuck EJ, Hirst EM, Sanderson CJ. Human interleukin- 5 (IL -5) regulates the 
production of eosinophils in human bone marrow cultures: comparison and interaction 
with IL -1, IL -3, IL -6, and GMCSF. Blood 1989;73:1504-1512.
GlaxoSmithKline Document Number CM2003/[ZIP_CODE]/07 Compound I D SB -240563. 
Investi gator’s brochure for Mepolizumab. Report date 23- MAY -2012.
Global I nitiative for Asthma (GINA): Global Strategy  for Asthma Management and 
Prevention, revised 2008. http://www.ginasthma.com/Guidelineitem.asp??l1=2&l2= 
Hamid Q, Azzawi M, Ying S, Moqbel R, W ardlaw AJ, Corrigan CJ, Bradley  B, Durham 
SR, Collins JV, Jeffery  PK et al. Expression of mRNA for interleukin -[ADDRESS_990308] 1991;87:1541-1546.
Humbert M, Corrigan CJ, Kimmitt P, Till SJ, Kay  AB, Durham SR. Rela tionship 
between IL -4 and IL-5 mRNA expression and disease severity  in atopic asthma. Am J 
Respir Crit Care Med 1997;156:704-708.
Juniper EF, Svensson K, Mőrk AC, St åhl E. Measurement properties and interpretation of 
three -shortened versions of the asthma control questionnaire. Resp Med 2005;99:[ADDRESS_990309] 2002;37:47s- 50s.
National Institutes of Health. National Heart, Lung, and Blood Institute (NHLBI). 
National Asthma Education and Prevention Program. Exper t Panel Report 3: guidelines 
for the diagnosis and management of asthma. August 2007. NIH publication no. 07 -4051 
Available at: http://www.nhlbi.nih.gov/guidelines/asthma/index.htm. Accessed 
November, 10, 2008.
Proceedings of the ATS workshop on refractory asthma: current understanding, 
recommendations, and unanswered questions. Am J Respir Crit Care Med
2000;162:2341-2351.
Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley  AM, Corrigan C, 
Durham SR, Kay  AB. Predominant TH2- like bronchoalveolar T-lymphocy te population 
in atopic asthma. N Engl J Med 1992;326:298- 304. 2017N325880_00
2012N139436_0 [ADDRESS_990310]  methacholine 
responsiveness in atopic asthma. J Allergy Clin Immunol 1993;92:397 -403.
Sampson HA, Munoz- Furlong A, Campbell RL , et. al. Second s ymposium on the 
definition and management of anaph ylaxis: summary  report --Second National I nstitute of 
Allergy  and Infectious Disease/Food Allergy  and Anaphy laxis Network symposium. J 
Allergy Clin Immunol 2006;117:391-397.
Wang JM, Rambaldi A, Biondi A, Chen ZG, Sanderson CJ, Mantovani A. Recombinant 
human interleukin 5 is a sele ctive eosinophil chemoattractant. Eur J Immunol
1989;19:[ADDRESS_990311] I. Eosinophils in asthma and 
other allergic diseases. Br Med Bull 2000;56:985-1003. 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
4811. APPENDICES
11.1. Appendix 1: Country  Specific Requirements
Country -Specific Requirements 
No country -specific requirements exist. 2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
4911.2. Appendix 2: A cceptable Birth Control
To be eligible for entry  into the study , females of childbearing potential must commit to 
consistent and correct use of an acceptable method of bir th control from the time of 
consent, for the duration of the trial, and for [ADDRESS_990312] stud y drug 
administration.
Male partner who is sterile prior to the female subject’s entry  into the study and 
is the sole sexual partner for that female sub ject 
Abstinence from penile -vaginal intercourse
Implants of levonorgestrel  or etonogestrel 
Injectable progestogen
Oral contraceptive (either combined or progestogen alone)
Estrogenic vaginal ring
Percutaneous contraceptive patches
Any intrauterine devic e (IUD) with a documented failure rate of less than 1% 
per year.
Male condom combined with a vaginal spermicide (foam, gel, film, cream, or 
suppository )
Male condom combined with a female diaphragm, either with or without a 
vaginal spermicide (foam, gel, f ilm, cream, or suppository )
Females of childbearing potential are defined as females with functioning ovaries (i.e., 
post-menarche, premenopausal women with no documented impairment of oviductal or 
uterine function that would cause sterility ). This categor y includes females with 
oligomenorrhea, females who are peri -menopausal, and y oung females who have begun 
to menstruate (adolescents).  The information on the lack of impairment of oviductal or 
uterine function that would cause sterility , can come from the site personnel’s:
Review of subject’s medical records
Medical examination of the subject
Interview with the subject on her medical history .
Females of non-childbearing potential are defined as females with functioning ovaries 
and with a documented tubal ligation or h ysterectomy ; or females who are 
postmenopausal defined as 12 months of spontaneous amenorrhea with an appropriate 
clinical profile, e.g. age appropriate, >45 years, in the absence of hormone replacement 
therap y (HRT).
In questionable cases a bl ood sample for follicle stimulating hormone (FSH) and estradiol 
will be obtained and analyzed to confirm childbearing potential.   2017N325880_00
2012N139436_0 3 CONFIDENTIA L
MEA115666
50Females on hormone replacement therap y (HRT) andwhose menopausal status is in 
doubt will be required to use one of the contraception methods listed above for females of 
childbearing potential if they wish to continue their HRT during the study .  Otherwise, 
they must discontinue HRT to allow confirmation of post -menopausal status prior to 
study  enrollment.  For most forms of HRT , at least 2 -4 weeks should elapse between the 
cessation of therapy and the blood draw; this interval depends on the t ype and dosage of 
HRT.  Following confirmation of their post- menopausal status, they  can resume use of 
HRT during the stud y without use of a contraceptive method.
Based on the absence of an identified reproductive hazard from preclinical studies, 
absence of a genotoxic potential, and very  low levels of mepolizumab that might be 
present in semen, there is no recognized risk for mepolizumab to affect human sperm or 
the fetus if transferred to a female partner via semen. Therefore, the use of condoms or 
other methods of contraception in the male study  subject is not required. 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
5111.3. Appendix 3: Liver Chemistry  Stoppi[INVESTIGATOR_23937] -IV Liver Safety Algorithms
ALT>3xULN
plus 
bilirubin >2x 
ULN (or
plus INR >1.5, 
if measured)*NoYes
Yes
•Instruct subject to stop investigational product (IP)
•Notify [COMPANY_004] + arrange clinical followup within 24-72h
•Perform liver chemistries and liver event follow  up 
assessments (serology, PK sample etc as in protocol) 
•Complete liver event CRF, SAE data collection tool if 
appropriate, + liver imaging +/or biopsy CRFs if  tests 
performed.
•Obtain weekly liver chemistries [**as far as possible] 
until resolved, stabilised or returned to baseline 
•Withdraw subject from study after liver chemistry 
monitoring c omplete + do not re -challenge with IP•Instruct subject to stop investigational product (IP)
•Notify [COMPANY_004] + arrange clinical followup within 24h
•Perform liver chemistries and liver event follow up 
assessments (serology, PK sample etc as in protocol) 
•Report as SAE (excl. hepatic impairment or cirrhosis 
studies)+ complete liver event CRF, SAE data collection 
tool, + liver imaging +/or biopsy CRFs if tests performed.
•Obtain twice weekly liver chemistries until resolved, 
stabilised or returned to baseline values
•Consultation w ith hepatologist /specialist recommended
•Withdraw subject from study after liver chemistry 
monitoring complete + do not re -challenge with IPHepatitis 
symptoms
or rash?NoAble to 
monitor 
weekly for 
4 weeks?Yes
No** YesContinue IP
Obtain twice 
monthly liver 
chemistries until 
normalised or 
back to baseline 
values
YesYesALT<3xULN 
+ bilirubin
<2xULN 
after ?4 
wks?
Yes
ALT 
>5xULN 
but 
<8xULNNo ALT  
>8xULNYesALT >5 
and 
<8xULN 
for >2 
wks
Yes NoALT>3xULN 
but <5xULN 
+ bilirubin
<2xULN+no 
symptomsNo Able to 
monitor 
weekly for 
>2 wks?No
NoNotify [COMPANY_004] within 24h 
to discuss subj ect 
safet y
Continue IP
Check liver chemistry 
weekly for 4 weeksYes
No
*INR value not applicable to patients on anticoagulants 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
5211.4. Append ix 4: A naphy laxis Criteria
Joint NI AID/FAAN Second Sy mposium on Anaphy laxis [ Sampson, 2006]. The criteria 
do not make a distinction based on underl ying mechanism. These criteria are summarized 
as follows:
1.Acute onset of an illness (minutes to several hours) with involvement of the skin, 
mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips -
tongue -uvula), and at least one of the following:
Respi[INVESTIGATOR_11310] (e.g., dy spnea, wheeze- bronchospasm, stridor, reduced 
PEF, hy poxemia) 
Reduced BP or associated sy mptoms of end- organ dy sfunction (e.g., hy potonia 
[collapse], sy ncope, incontinence)
2. Two or more of the following that occur rapi[INVESTIGATOR_11312] a likel y allergen 
for that patient (minutes to several hours):
Involvement of the skin -mucosal tissue (e.g., generalized hives, itch -flush, 
swollen lips -tongue -uvula)
Respi[INVESTIGATOR_11310] (e.g., dy spnea, wheeze
-bronchospasm, stridor, reduced 
PEF, hy poxemia)
Reduced BP or associated sy mptoms (e.g., h ypotonia [collapse], syncope, 
incontinence)
Persistent gastrointestinal sy mptoms (e.g., crampy abdominal pain, vomiting)
3.Reduced BP after exposure to known allergen for that patient (minutes to several 
hours):
Infants and children: low sy stolic BP (age specific) or greater than 30% decrease 
in sy stolic BP
Adults: sy stolic BP of less than 90 mm Hg or greater than 30% decrease from 
that person’s baseline 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
5311.5. Appendix 5: Cardiovascular Screening Questions
At screening each subject should be asked the f ollowing:
Unrelated to the s ymptoms y ou experience with y our asthma:
1. Do you have any pain or discomfort (such as pressure) in your chest? 
h.If yes, does this pain/discomfort/pressure go to other areas of your bod y such as 
neck, jaw, throat, or down y our arm s (including a numbness feeling in y our arm) 
when it occurs?
2.When you walk at an ordinary pace on a level surface does this produce chest 
pain? If yes, respond to a and b:
a.Does this chest pain or discomfort occur when you are not doing an y activities 
such as resting in bed or sitting in a chair?  
b. Has this chest pain/discomfort been more frequent or more intense or last longer 
or come on with less exertion lately ?
3. When you walk uphill or hurry does this produce chest pain/discomfort?
4.Do you use or have you been previously prescribed nitroglycerine to relieve the 
discomfort?  
If yes, have you needed to increase the number of pi[INVESTIGATOR_725488] ?
i.If the subject responds “yes” to any of the above questions a study physician 
should fu rther assess for the presence of undiagnosed or unrecognized angina 
when evaluating Exclusion Criterion 4.  
Subject responses will be entered into the eCRF. 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
5411.6. Appendix 6: [LOCATION_001] Heart A ssociation Functional 
Classification of Congestive Heart Failure
CLASS PATIENT SYMPTOMS
I Patients with cardiac disease but resulting in no limitation of physical activity. 
Ordinary physical activity does not cause undue fatigue, palpi[INVESTIGATOR_332], dyspnea or 
anginal pain.
II Patients with cardiac disease resulting in slight lim itation of physical activity. 
They are comfortable at rest. Ordinary physical activity results in fatigue, 
palpi[INVESTIGATOR_332], dyspnea or anginal pain
III Patients with cardiac disease resulting in marked limitation of physical activity. 
They are comfortable at rest. Less than ordinary activity causes fatigue, 
palpi[INVESTIGATOR_332], dyspnea or anginal pain
IV Patients with cardiac disease resulting in inability to carry on any physical activity 
without discomfort. Symptoms of heart failure or the anginal syndrome may be 
present even at rest. If any physical activity is undertaken, discomfort increases
Adapted from American Heart Association, 2012 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
5511.7. Appendix 7: Protocol Changes
Scope
This amendment applies to all site s
Protocol changes specified in Amendment No. 1 are summarized below:
To clarify  that the rationale and objective of the study  includes long -term provision 
of mepolizumab therap y to subjects who have severe asthma and participated in 
MEA112997
To clarify  that onl y monoclonal antibodies are excluded, rather than all biologics
To clarify  reason for more frequent safety  monitoring at the start of the study  
To correct Inclusion criterion 5 from Randomisation Visit to Visit 2
To add exclusion criterion for sign ificant cardiovascular disease
To correct inconsistencies between protocol text and the Time and Events Table
To correct bilirubin exclusion criterion at visit 2
To expand on requirements for designating a subject as lost to follow -up
To add visit window f or the follow -up visit
To move baseline spi[INVESTIGATOR_725474]
To clarify  that all subjects will have an immunogenicity  test [ADDRESS_990313] dose
To correct Section [IP_ADDRESS] wording “Efficacy ” to “Safet y”
To add reference to support Appendix 6 and remove 3 references which are not cited 
in the protocol.
To add Appendix 5 and Appendix 6 and amended Section 6.1 and Section 6.3.9. to 
support the determination of exclusion criteria 4
Protocol Changes Amendment 1:
Section RATIO NALE
Additional Text:
This trial also provides subjects who participated in the MEA112997 study, and meet the 
current trial eligibility  criteria, the option of receiving treatment with mepolizumab, as an 
add-on to their standard of care treatment for sever e asthma.  2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
56Section OBJECTIVES 
Additional Text:
To provide long -term treatment with mepolizumab to subjects who participated in 
MEA112997
Section STUDY DESIGN
Original Text:
Subjects will remain on standard of care asthma therap y, which may  be adjusted du ring 
the study , at the discretion of their phy sician. The use of Xolair (omalizumab) or an y 
other biologic will not be permitted during the course of the stud y. 
Subjects will be monitored in the clinic approximately  every  4 weeks to assess adverse 
events and asthma status.  The Asthma Control Questionnaire- 5 (ACQ) will be used to 
assist the investigator in assessing the subject’s asthma status along with spi[INVESTIGATOR_725476].  As some subjects may  have previously  received placebo while 
participa ting in the MEA112997 study  and are naive to mepolizumab, safety lab 
monitoring will be more frequent at the start of the study .  Appropriate safety  labs will be 
drawn prior to starting treatment and then at week 4, 8, 12, 24, [ADDRESS_990314] of care asthma therap y, which may  be adjusted during 
the study , at the discretion of their phy sician. The use of Xolair (omalizumab) or an y 
other monoclonal antibody will not be permitted during the course of the study . 
Subjects will be monitored in the clinic approximately  every  4 weeks to assess adverse 
events and asthma status.  The Asthma Control Questionnaire -5 (ACQ) will be used to 
assist the investigator in assessing the subject’s asthma status alon g with spi[INVESTIGATOR_725476].  As some subjects may  have previously  received placebo while 
participating in the MEA112997 study  and are naive to mepolizumab, safety lab 
monitoring will be more frequent at the start of the study .  Appropriate safe ty labs will be 
drawn prior to starting treatment and then at week 4, 8, 12, 24, 36 and 48.  Thereafter, 
these will be collected every  24 weeks.  Labs will also be obtained at 12 weeks after 
discontinuing mepolizumab.  Subjects discontinuing mepolizumab tr eatment should be 
monitored for exacerbation of their asthma. 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
57Serum samples for anti- mepolizumab antibody  measurements will be obtained from all 
subjects at  Weeks 0,4, 24 and 48 of the initial year, week 24 and 48 for every  additional 
year, as well as at the Follow -up Visit. Any  anti-mepolizumab antibody  positive sample 
will be tested for neutralization antibody .
Section 1.2 Rationale
Added text:
This trial also provides subjects who participated in the MEA112997 study, and meet the 
current trial eligibili ty criteria, the option of receiving treatment with mepolizumab, as an 
add-on to their standard of care treatment for severe asthma. 
Section 2 Objectives:
Added Text:
To provide long -term treatment with mepolizumab to subjects who participated in 
MEA112997
Section 3.1 Study Design:
Original Text:
Subjects will remain on standard of care asthma therap y, which may  be adjusted during 
the study , at the discretion of their phy sician. The use of Xolair (omalizumab) or an y 
other biologic will not be permitted during the course of the stud y.  
Revised Text:
Subjects will remain on standard of care asthma therap y, which may  be adjusted during 
the study , at the discretion of their phy sician. The use of Xolair (omalizumab) or an y 
other monoclonal antibody will not be permitted during the course of the study .  
Original Text:
At each clinic visit, adverse events will be assessed, and appropriate safet y labs will be 
obtained as per the Time and Events schedule (see Table 2 and Table 3).  As laboratory  
results have not be en characterized when subjects reinstitute treatment with 
mepolizumab, safety  lab monitoring will be more frequent at the start of the study .  
Exacerbations will also be reviewed at each clinic visit.
Revised Text
At each clinic visit, adverse events will be assessed, and appropriate safet y labs will be 
obtained as per the Time and Events schedule (see Table 2 and Table 3).  As some 
subjects will be naive to mepolizumab , safet y lab monitoring will be more frequent at 
the start of the stud y.  Exacerbations w ill also be reviewed at each clinic visit. 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
58Section 4.2 Inclusion Criteria:
Original Text:
A serum pregnancy  test is required of all females. at the initial Screening Visit 
(Visit 1).  I n addition, a urine pregnancy  test will be performed for all females pr ior 
to randomisation, during each scheduled stud y visit prior to the injection of 
investigational product, and during the Follow- up Visit. 
Revised Text:
A serum pregnancy  test is required of all females. at the initial Screening Visit 
(Visit 1).  In addit ion, a urine pregnancy  test will be performed for all females prior 
toVisit 2, during each scheduled study  visit prior to the injection of investigational 
product, and during the Follow -up Visit. 
Section 4.3 Exclusion Criteria:
Added Text:
4.Cardiovascular: Subjects who have severe or clinically  significant 
cardiovascular disease uncontrolled with standard treatment. Including but not 
limited to:
a.known ejection fraction of <30% OR
b.severe heart failure meeting [LOCATION_001] Heart Association Class I V (see 
Appendi x6  classification OR
c.hospi[INVESTIGATOR_561879] 12 months prior to Visit 1 for severe heart failure 
meeting [LOCATION_001] Heart Association Class III (see Appendix 6) OR
d. angina diagnosed less than 3 months prior to Visit 1 or at Visit 1 
Section 4.5 Withdrawal Crite ria:
Original Text:
Subjects are free to discontinue participation in the study  at any time. Every  effort should 
be made to have the subject return for a Follow -up visit [ADDRESS_990315] to assure their 
safet y. These efforts should be documented in the clinic notes at the site. 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
59Revised Text:
Subjects are free to discontinue participation in the study  at any time. Every  effort should 
be made to have the subject return for a Follow -up visit [ADDRESS_990316] after 3 documented attempts via 2 different 
methods (phone, text, e -mail, certified letter, etc). These efforts should be 
documented in the clinic notes at the site.
Subjects may  also be withdrawn from this study  if mepolizumab becomes commerc ially 
available in the respective country , marketing of mepolizumab is no longer being sought 
in the respective country , or upon decision of the sponsor to discontinue further 
development of mepolizumab.
The primary  reason for withdrawal will be recorded i n the eCRF and any data collected 
up until the point of withdrawal will be used in the data anal yses. 
Section 5.7.2 Prohibited Medications:
Original Text:
MedicationWashout Time
Prior to Screening Visit
Investigational drugs 1 month or 5 half -lives whi chever is 
longer
Omalizumab [Xolair] 130 days
Other biologicals 5 half -lives
Experimental anti -inflammatory drugs (non biologicals) 3 months
Revised Text:
MedicationWashout Time
Prior to Screening Visit
Investigational drugs 1 month or 5 half -lives whichever is 
longer
Omalizumab [Xolair] 130 days
Other monoclonal antibodies 5 half -lives
Experimental anti -inflammatory drugs (non biologicals) 3 months
Section 6 Study Assessments and Procedures:
Added Footnote:
6.Follow -up visit window is  2 weeks
Moved initial sprirometry from screen visit to Visit 2 (Baseline) 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
60Section 6.1 Critical Baseline Assessments:
Original Text:
Cardiovascular medical history /risk factors will be assessed at baseline.
Revised Text:
Cardiovascular medical history /risk factors will be assessed at screening. This 
assessment must include a review of the subject responses to the 
cardiovascular assessment questions (See Appendix 5) and height, weight, 
blood pressure, medical conditions, and family history of premature 
cardiovascular disease.
Section 6.3.5: Cardiovascular Events
Added Text:
Investigators will be required to fill out event specific pages in the eCRF for the 
following AEs and SAEs:  
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thrombosis
Deep Venous Thrombosis
Revascularization
Cardiovascular events information should be recorded on the corresponding eCRF pages 
within one week of when the AE/SAE(s) are first reported.  Please refer to Section 6.3.9 
for timelines for reporting AE/SAEs.
Section 6.3.6: Death Events
In addition, all deaths will require completion of a specific death data collection page in 
the eCRF.  The death data collection page in the eCRF includes questions regarding 
cardiovascular (including sudden cardiac death) and non- cardiovascular death.
Death information should be recorded on the death eCRF page within one week of when 
the death is first reported.
Please r efer to Section 6.3.9 for timelines for reporting SAEs. 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
61Section 6.3.9 Prompt Reporting of Serious Adverse Events and Other Events to 
[COMPANY_004]
Original Text:
Initial Reports Follow -up Information on a Previous 
Report
Type of Event Time Frame Documents Time Fra me Documents
All SAEs 24 hours “SAE” data 
collection tool24 hours Updated “SAE” data 
collection tool
Revised Text:
Initial Reports Follow -up Information on a Previous 
Report
Type of Event Time Frame Documents Time Frame Documents
All SAEs 24 hours “SAE” data 
collection tool24 hours Updated “SAE” 
data collection tool
“CV events” 
and/or “death” 
data collection 
tool(s ) 
Section 6.4 Immunogenicity:
Original Text:
For subjects who prematurely  withdraw from the study , immunogenicity  testing will 
occur at [ADDRESS_990317] dose.
Revised Text:
For allwho prematurel y withdraw from the stud ysubjects, immunogenicity  testing will 
occur at [ADDRESS_990318] dose.
Section [IP_ADDRESS] Safety Analyses:
Original Text:
All efficacy  endpoints will be summa rised using descriptive statistics. Further details will 
be provided in the RAP.
Revised Text:
All safety endpoints will be summarised using descriptive statistics. Further details will 
be provided in the RAP. 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
62Section 10 References:
Added text:
American He art Association.  Classes of Heart Failure.  Available at: 
http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes -
of-Heart -Failure_UCM_306328_Article.jsp.  Accessed [ADDRESS_990319] 2012.
Deleted text:
Dolan P, Cookson R. A qualitative st udy of the extent to which health gain matters when 
choosing between groups of patients. Health Policy 2000;51:19 -30.
Flood -Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L , Robinson 
D, Wenzel S, Busse W, Hansel T and Barnes N. A study  toevaluate safety  and efficacy  
of mepolizumab in patients with moderate persistent asthma. Am J Resp Crit Care 
2007 ;176:[ADDRESS_990320] I D. M epolizumab and exacerbations of 
refractory  eosinophilic asthma. N Engl J Med 2009;360:973 -984. 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
63Section 11.5 Appendix 5
Added text:
Appendix [ADDRESS_990321] should be asked the following:
Unrelated to the s ymptoms y ou experience with y our asthma:
1. Do you have any pain or discomfort (such as pressure) in your chest? 
a.If yes, does this pain/discomfort/pressure go to other areas of your bod y such as 
neck, jaw, throat, or down y our arms (including a numbness feeling in your arm) 
when it occurs?
2.When you walk at an ordinary pace on a level surface does this produce chest 
pain? If yes, respond to a and b:
a.Does this chest pain or discomfort occur when you are not doing an y 
activities such as resting in bed or sitting in a chair?  
b. Has this chest pain/discomfort been more frequent or more intense or last 
longer or come on with less exertion lately ?
3. When you walk uphill or hurry does this produce chest pain/discomfort?
4.Do you use or have you been previously prescribed nitr oglycerine to relieve the 
discomfort?  
If yes, have you needed to increase the number of pi[INVESTIGATOR_725488] ?
b.If the subject responds “yes” to any of the above questions a study physician 
should further assess for the presence o f undiagnosed or unrecognized angina 
when evaluating Exclusion Criterion 4.  
Subject responses will be entered into the eCRF. 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
64Section 11.6 Appendix 6
Added Text:
Appendix [ADDRESS_990322]. If any physical activity is undertaken, discomfort increases
Adapted from American Heart Association, 2012.
Appendix 7
Original Text:
1.Liver Function: Liver Function Tests at screening that meet an y of the following: 
ALT ≥[ADDRESS_990323] (upper limit of normal) 
AST ≥2 x UL N 
Alk Phos ≥2 x UL N 
Bilirubin ≥[ADDRESS_990324] (isolated bilirubin ≥[ADDRESS_990325] bilirubin is <35%   
Revised Text:
5.Liver Function: Liver Function Tests at screeni ng that meet an y of the following: 
ALT ≥[ADDRESS_990326] (upper limit of normal) 
AST ≥2 x UL N 
Alk Phos ≥2 x UL N 
Bilirubin >1.5 x UL N (isolated bilirubin >1.5x ULN is acceptable if bilirubin is 
fractionated and direct bilirubin is <35%) 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
65Protocol A mendment Number 02
Scope: This amendment applies to all sites.
Protocol Changes specified in Amendment No. 2 are summarised below:
To add two additional immunogenicit y sample assessment time points when the 
100mg vial is introduced. 
To allow other s yringe sizes for stud y drug administration
To allow for stud y drug administration in the upper thigh or the arm
To add the prohibited non-drug therapi[INVESTIGATOR_725475] 5.7.2
To list Adverse Events and Serious Adverse Events on the same line in Table 3
To correct a formatting error for Section 4.6
To remove specific test name [CONTACT_725495] C positive sample
To delete redundant text in Section [IP_ADDRESS]
To remove from Section 6.3.7 the requirement to report outcome of pregnancy in 
female partners of male subjects
To include anal yses of immunogenicit y data in Section 8.3 and to clarify  when 
interim analy ses will be performed
Study Design:
Added Text:
A maximum of two additional anti- mepolizumab antibody  samples will be obtained; one 
immediately  prior to the first dose and the other prior to the second dose with the 100mg 
mepolizumab vial. I f the first or second dose coincides with a visit where an 
immunogenicit y sample is alread y required, it is not necessary to obtain an additional 
sample. 
Added Text:
All subjects will be dosed with the 250mg vial up until such time that the 100mg vial is 
available at the site and all regulatory /ethics approvals have been received.  Once the 
100mg vial is available at the site, all subjects will switch to dosing with 100mg vial.  
Subjects will then be dosed with the 100mg vial for the duration of the study.  
Section 4.6
Corrected formatting to add the Section number. 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
66Section 5.2 Dosage and Administration:
Original Text
Once the mepolizumab vial is reconstituted, [ADDRESS_990327] .
Revised Text:
Once the mepolizumab vial is reconstituted, [ADDRESS_990328] .
Section 5.3 Treatment Assignmen t:
Original Text:
All subjects will receive 100 mg of mepolizumab administered subcutaneously  into the 
upper arm approximately every  4 weeks.  
Revised Text:
All subjects will receive 100 mg of mepolizumab administered subcutaneously  into the 
upper thigh o r the back of the upper arm approximately  every  4 weeks.  
Section 5.7.2 Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_725489]:
Additionally , Bronchial Thermoplasty  and Radiotherapy  are excluded for [ADDRESS_990329] Year Table 2:
Original Text:
Hepatitis B Surface Antigen and Hepatitis C antibody ( if Hepatitis C antibody positive, a hepatitis C RIBA should be 
automatica lly performed on the same sample to confirm the result)
Revised Text:
Hepatitis B Surface Antigen and Hepatitis C antibody ( if Hepatitis C antibody positive, a hepatitis C confirmatory test 
should be automatically performed to confirm the result)
Added Text:
* Take additional immunogenicity sample prior to first dose with 100mg vial and prior to the second dose with the 
100mg vial 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
67Table 3 Time and Events Table for Additional Years:
Original Text:
Adverse Events
Revised Text:
Adverse Events/SAEs
Added Te xt:
* Take additional immunogenicity sample prior to first dose with 100mg vial and prior to the second dose with the 
100mg vial. Maximum of 2 additional samples
Section [IP_ADDRESS] Definition of an AE
Deleted Text:
The signs and sy mptoms and/or clinical sequ elae resulting from lack of efficacy  will be 
reported if they  fulfill the definition of an AE or SAE.  Also, “lack of efficacy ” or 
“failure of expected pharmacological action” also constitutes an AE or SAE.
Deleted Text:
Section 6.3.7 Pregnancy:
In additio n, the investigator must attempt to collect pregnancy  information on any  female 
partners of male study  subjects who become pregnant while the subject is enrolled in the 
study .  Pregnancy  information must be reported to [COMPANY_004] as described above.
Section 6.4 Immunogenicity
Added Text:
Two additional anti- mepolizumab antibody  samples will be obtained;   One prior to the 
first dose and the other prior to the second dose with the 100mg mepolizumab vial. 
Original Text:
Section 8.3.4 Interim Analysis
Interim anal ysis will be performed on an annual basis and at other times as needed in 
order to provide open -label safet y data to inform the risk -benefit assessment of 
mepolizumab in severe asthma.
Revised Text:
Interim anal ysis will be performed as needed in order to pr ovide open -label safet y data to 
inform the risk -benefit assessment of mepolizumab in severe asthma. 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
68Original Text:
Section [IP_ADDRESS] Health Outcome Analyses
No health outcomes endpoints are defined for this study .
Revised Text:
Section [IP_ADDRESS] Immunogenicity Analyses
All immunogenicity  endpoints will be summarised using descriptive statistics. The 
number and percentage of subjects with positive neutralizing antibodies before and after 
the introduction of the 100mg mepolizumab vial will be tabulated. Further d etails will be 
provided in the RAP.
Deleted Text:
Section [IP_ADDRESS] Pharmacodynamic Analyses
No pharmacod ynamic endpoints are defined for this study.
Appendix 7 Amendment 01
Added Text:
Appendix 7
Original Text:
2.Liver Function: Liver Function Tests at screening that meet an y of the following: 
ALT ≥[ADDRESS_990330] (upper limit of normal) 
AST ≥2 x UL N 
Alk Phos ≥2 x UL N 
Bilirubin ≥[ADDRESS_990331] (isolated bilirubin ≥[ADDRESS_990332] bilirubin is <35%   
Revised Text:
2.Liver Function: Liver Function Tests at screeni ng that meet an y of the following: 
ALT ≥[ADDRESS_990333] (upper limit of normal) 
AST ≥2 x UL N 
Alk Phos ≥2 x UL N 
Bilirubin >1.5 x UL N (isolated bilirubin >1.5x ULN is acceptable if bilirubin is 
fractionated and direct bilirubin is <35%) 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
69Protocol Amendment Numbe r 03 Changes
Scope: This amendment applies to all sites.
Protocol Changes specified in Amendment No. 3 are summarised below:
Change No. 1: To change the Follow -up visit from [ADDRESS_990334] has since 
improved and the immunogenic ity sample at the Exit visit is now sufficient.   
Study Design
Original text: 
Labs will also be obtained at 12 weeks after discontinuing mepolizumab.  
Changed to:
Labs will also be obtained at 4 weeks after discontinuing mepolizumab.  
Additional paragr aph added to Study  Design and to Section 3.1 Study  Design:
The study  closure process will begin, on a country by  [CONTACT_619291], as mepolizumab 
becomes commerciall y available for prescription.  Please see the SPM for more details.
Section 4.5 Withdrawal Cr iteria
Original text:
Every  effort should be made to have the subject return for a Follow -up visit [ADDRESS_990335] mepolizumab injection.
Changed to:
Every  effort should be made to have the subject return for a Follow -up visit [ADDRESS_990336] mepoliz umab injection.
Section 6 Table 2 Study Assessments and Procedures, column header
Original text:
Follow -up [ADDRESS_990337] injection
Changed to:
Follow -up [ADDRESS_990338] injection 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
70Section 6 Study Assessments and Procedures (Footnote No. 6)
Original text:
6.  Follow -up visit window is  2weeks
Changed to:
6.  Follow -up visit window is  1weeks
Section 6 Table 3 Study Assessments and Procedures, column header
Original text:
Follow -up [ADDRESS_990339] injection
Changed to:
Follow -up [ADDRESS_990340] injection
Section 6 Table 3 Study Assessments and Procedures (Footnote No. 4)
Original text:
4.  Follow -up visit window is  2weeks
Changed to:
4.  Follow -up visit window is  1weeks
Section 6.3.8 Time Period and Frequency of Detecting AEs and SAEs
Original text: 
AEs will be collected from the start of investigational product (Visit 2) and until the 
follow up visit ( [ADDRESS_990341] injection).
Changed to:
AEs will be collected from the start of investigational product (Visit 2) and until th e 
follow up visit ( [ADDRESS_990342] injection).
Section 6.4 Immunogenicity
Original text: 
For all subjects, immunogenicity  testing will occur at [ADDRESS_990343] dose.
Changed to:
For all subjects, immunogenicity  testing will occur at [ADDRESS_990344] dose. 2017N325880_00
2012N139436_03 CONFIDENTIA L
MEA115666
71Change No. 2: To update the time limit from reconstitution to administration of I P
Section 5.2 Dosage and Administration
Original text:
Once the mepolizumab vial is reconstituted, [ADDRESS_990345] .
Changed to:
Once the mepolizumab vial is reconstituted, 100 mg of mepolizumab should be drawn 
into a poly propylenesyringe, and administered according to the instructions in the SPM. 2017N325880_00